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 ABSTRACT 
 
The purpose of this research was to study the synthesis and remodeling of 
extracellular matrix (ECM) by fibroblasts with special emphasis on the culture 
environment (media composition and initial ECM composition) and the resulting 
mechanical integrity of the ECM. This was investigated by culturing fibroblasts for 3 
weeks in a variety of culture conditions consisting of collagen gels, fibrin gels, or media 
permissive to the self-production of ECM (Cell-Derived Matrix), and quantifying the 
mechanics of the resulting ECM. The mechanical characteristics were related to the 
biochemistry of the resulting ECM, notably in terms of collagen accumulation and 
collagen fibril diameters. The ultimate tensile strength (UTS) of the collagen gels and 
fibrin gels at the end of the 3-week period was 168.5 ± 43.1 kPa and 133.2 ± 10.6 kPa, 
respectively. The ultimate tensile strength of the cell-derived matrices was 223.2 ± 9 kPa, 
and up to 697.1 ± 36.1 kPa when cultured in a chemically-defined medium that was 
developed for the rapid growth of matrix in a more defined environment. Normalizing the 
strength to collagen density resulted in a UTS / Collagen Density in these groups of 6.4 ± 
1.9 kPa/mg/cm3, 25.9 ± 2.4 kPa/mg/cm3, 14.5 ± 1.1 kPa/mg/cm3, and 40.0 ± 1.9 
kPa/mg/cm3, respectively. Cells were synthetically more active when they produced their 
own matrix than when they were placed within gels. The resulting matrix was also 
significantly stronger when it was self-produced than when the cells rearranged the 
matrix within gels that corresponded to a significantly larger fraction of non-acid and 
pepsin extractable collagen. These studies indicate that cell-derived matrices have 
potential both as in vitro wound healing models and as soft connective tissue substitutes.  
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Thesis Objectives 
 
The purpose of this Master’s Thesis was to study the synthesis and remodeling of 
extracellular matrix (ECM) by fibroblasts with special emphasis on the culture 
environment (media composition and initial ECM composition) and the resulting 
mechanical integrity of the ECM. This was investigated by culturing fibroblasts for 3 
weeks in a variety of culture conditions consisting of collagen gels, fibrin gels, or media 
permissive to the self-production of ECM, and quantifying the mechanics of the resulting 
ECM. The mechanical characteristics were related to the biochemistry of the resulting 
ECM, notably in terms of collagen accumulation and collagen fibril diameters. The 
hypothesis was: Cell-derived matrices (CDMs) are stronger than fibroblast populated 
collagen gels and fibroblast populated fibrin gels due to a greater collagen density and 
fibril diameter of the self-produced collagen in the CDM. To accurately determine these 
differences, all groups were grown in parallel with the same number and type of cells, fed 
with the same media at the same frequency, started and grown for the same period of 
time, grown next to each other on the same 6-well plates, and overall maintained in the 
same environment. 
Due to the slow growth and development of self-produced ECM, a method of 
quickly growing strong and thick cell-derived matrices in vitro was developed. This 
involved seeding low passage cells at “superconfluent” densities, or densities where the 
cells were stacked next to and top of each other, on TransWells™ and feeding the 
constructs with a chemically-defined medium that was developed. The components and 
their individual concentrations in this chemically-defined medium were chosen according 
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to whether they significantly increased the thickness and/or strength of cell-derived 
matrices. The relatively few components in this chemically-defined medium aided in 
gaining insight into the effects of these components on the growth and strengthening of 
cell-derived matrices. This provided insight into how different nutritional components 
influence the mechanisms of growth and strengthening of cell-derived matrices.  
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Introduction 
 
Living tissue equivalents (LTE), notably cell-seeded collagen and fibrin gels, 
have been used extensively as in vitro wound-healing models as well as models for tissue 
remodeling (for review see (Grinnell, 2003)). More recently, tissue-equivalents have also 
started to gain considerable attention as replacements for lost or damaged connective 
tissue (e.g., Apligraf™ from Organogenesis, Inc.). Living tissue-equivalents have several 
advantages over synthetic alternatives including being a natural cell substrate, allowing 
cellularity to be achieved directly, and being conducive to cell spreading and extracellular 
matrix (ECM) formation (Neidert et al., 2002).  
Over the last two decades, models of fibroplasia that are completely cell-derived 
have also been developed. This has allowed the study of tissue formation solely from 
cells in vitro. Several research groups have demonstrated that, given a permissive 
environment, fibroblasts can be induced to produce a thin, 3-dimensional sheet of 
extracellular matrix material in vitro (Grinnell et al., 1989; Clark et al., 1997; Ishikawa et 
al., 1997; L'Heureux et al., 1998; Ohgoda et al., 1998).  These cell-derived matrices 
(CDM) are produced by slowly proliferating multilayered fibroblasts that become 
surrounded by the dense extracellular matrix that is composed in large part by 
supermolecularly organized collagen (Grinnell et al., 1989; Ishikawa et al., 1997). The 
fibroblasts in this self-produced environment assume a synthetic phenotype (Kessler et 
al., 2001) characterized by low cell proliferation, high collagen accumulation, fibrillar 
fibronectin organization, and the formation of actin stress fibers and focal adhesions.  
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Although the biological and biochemical characteristics of these matrices have 
been studied to some extent, little is known about their mechanical characteristics and 
how it relates to the biochemical composition of these materials. From studies by Clark et 
al. (1997) and L'Heureux et al. (1998), their structure and composition appears to more 
closely approximate native tissue than “reconstituted” ECM (e.g., collagen gels).  Indeed, 
Auger and colleagues (1998) have demonstrated significantly higher burst strength of 
completely biological human blood vessel equivalents (L'Heureux et al., 1998) produced 
by laminating several of these “self-assembled matrices” into a tubular geometry than has 
been obtained with collagen or fibrin tubes.  Preliminary studies of linear “tendon 
equivalents” produced using this technology also indicate that these cell-derived matrices 
have strengths approaching native tissues (Calve et al., 2003). Tissue equivalents of high 
strength, such as CDMs, are in high demand since current shortages of load-bearing 
tissue has created a need for man-made tissues that can withstand in vivo mechanical 
forces (Gildner and Hocking, 2003). As with native connective tissues, the mechanics of 
CDM produced in vitro depends not only on the features of individual cells and matrix 
molecules, but also on the complex organizational and reciprocal interactions of 
collections of cells and their surrounding matrix (Grinnell, 2003). The biochemical 
composition and arrangement of the ECM by fibroblasts influence the mechanical 
characteristics of the ECM. Thus, CDM provides a powerful tool for studying the 
functional (mechanical) outcomes of these cell-matrix interactions in a controlled 
environment has similarities to in vivo fibroplasia and the early stages of wound-healing. 
However, a major limitation of CDMs is that they are very thin and take a long time to 
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grow, generally in the order of months (Auger et al., 2000), whereas collagen gels and 
fibrin gels can be developed in only a few days (Grinnell, 1994). 
The aim of the current study was to compare the biomechanical and biochemical 
properties of CDMs, collagen gels and fibrin gels to gain insight into the synthesis and 
remodeling of ECM by fibroblasts.  Additionally, to facilitate more rapid studies, we 
sought to develop a chemically-defined medium permissive to quick self-production of 
strong and thick ECM in vitro that may also be of value for developing functional soft 
connective tissue substitutes. 
 
 
Materials and Methods 
All components from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated. 
 
Cells 
Human neonatal foreskin fibroblasts (HFFs) were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). HFF cultures were maintained in T-300 
tissue culture flasks (BD Biosciences, Bedford, MA) with high glucose Dubelco’s 
modified Eagle’ medium (DMEM, Mediatech, Herndon, VA) supplemented with 10% 
bovine calf serum (BCS, Hyclone, Logan, UT), and 1% penicillin/streptomycin/ 
ampothericin B (Invitrogen, Carlsbad, CA). HFFs were incubated at 37°C in humidified, 
10% CO2 conditions. Cells were harvested at 90% confluency with a 10min application 
of 0.25% trypsin/0.05% EDTA solution (Mediatech). Two million, passage 5 cells were 
used for each sample in all experiments. 
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Standard Serum-Supplemented Medium 
 The collagen gels, fibrin gels and cell-derived matrices (CDMs) were fed with a 
serum-supplemented medium consisting of DMEM with 10% fetal bovine serum (FBS, 
ATCC), 150µg/ml (519µM) L-ascorbic acid phosphate magnesium salt n-hydrate (Wako 
Pure Chemicals, Japan), and 1% penicillin/streptomycin/ampothericin B (Invitrogen). 
Long-lasting L-ascorbic acid phosphate magnesium salt n-hydrate (Ishikawa et al., 1997) 
was added to stimulate collagen synthesis (Grinnell et al., 1989; Hata and Senoo, 1989; 
Huang et al., 1993; Kurata et al., 1993; Ishikawa et al., 1997; Girton et al., 2000; 
Hoerstrup et al., 2000; Laplante et al., 2001; Pouliot et al., 2002). The L-ascorbic acid 
concentration was 80% higher than the 50µg/ml (289µM) of L-ascorbate used by 
Grinnell et al. (1989). 
 
Collagen Gel, Fibrin Gel and Cell-Derived Matrix Preparation 
Fibroblast-populated collagen gels (CGs) were prepared according to the methods 
of Elsdale and Bard (1972) by mixing 0.2ml of collagen stock solution (5mg/ml of 5mM 
HCl-extracted rat tail tendon collagen in 5mM acetic acid), 0.05ml 5X DMEM, 0.65ml 
DMEM (Mediatech) with cells, 0.1ml fetal bovine serum (FBS, ATCC), 150µg L-
ascorbic acid phosphate magnesium salt n-hydrate (Wako Pure Chemicals) and 1% 
penicillin/streptomycin/ampothericin B (Invitrogen) at room temperature. One milliliter 
of the resulting solution was added into each 24mm diameter well. The initial collagen 
concentration was 1.0mg/ml, and the initial cell concentration was 2,000,000 cells/ml in 
10% FBS. 
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Fibroblast-populated fibrin gels (FGs) were prepared based on the methods of 
Tuan et al. (1996) and Neidert et al. (2002). Briefly, HFFs in DMEM with 10% fetal 
bovine serum, 150µg/ml L-ascorbic acid phosphate magnesium salt n-hydrate, and 1% 
penicillin/streptomycin/ampothericin B were added to a fibrinogen (Sigma F4753 type 
IV) solution. One ml samples were mixed with 4 units of bovine thrombin (Sigma 
T7513) at room temperature. One ml of the resulting solution was added into each 24mm 
diameter well.  The initial fibrinogen concentration was 1.0mg/ml, and the initial cell 
concentration was 2,000,000 cells/ml in 10% FBS.  
Standard cell-derived matrices (CDMs) were prepared by mixing the 2 million, 
passage 5 HFFs with DMEM, 10% FBS, 150µg/ml L-ascorbic acid phosphate 
magnesium salt n-hydrate, and 1% penicillin/streptomycin/ampothericin B (serum-
supplemented stock medium) at room temperature into a final volume of 1ml per sample. 
The initial cell concentration was 2,000,000 cells/ml in 10% FBS.  
The 1ml samples of collagen gels, fibrin gels, and CDMs were pipetted onto 
24mm diameter, porous inserts (0.4µm TransWells™, Corning Life Sciences, Acton, 
MA) suspended above standard 6-well plates, and allowed to sit undisturbed at room 
temperature. The semi-permeable culture surfaces allowed a greater volume of nutrient 
media to be used at each feeding without compromising the oxygen diffusion so that the 
media could be changed less frequently than once per day required for these high density 
cultures when cultured on standard plastic plates. Furthermore, the membranes provided 
a shorter diffusion distance for gases and nutrients for cells on the basal side of the 
matrices allowing cell-derived matrices to grow more than 50% thicker than in regular 6-
well plates (data not shown). After a 1 hour period, 3 ml of standard serum-supplemented 
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medium was carefully added below and 1 ml above each sample and the samples were 
incubated at 37°C in humidified, 10% CO2 conditions. Samples were fed every other day 
(3 ml below and 2ml above) with the standard serum-supplemented medium for 3 weeks. 
To reduce experimental variability, all groups were grown in parallel with the same 
number and type of cells, fed with the same standard serum-supplemented media at the 
same time, started and grown for the same period of time, grown next to each other on 
the same 6-well plates, and maintained in the same environment.  
 
Chemically-Defined Media 
To efficiently study cell-derived models of wound healing and tissue development 
in vitro, a method of growing CDMs quickly and economically with sufficient thickness 
and strength was needed. To study the effects of growth factors and media components 
on CDM growth without the confounding effects of serum (undefined and complex 
composition), a chemically-defined media was developed to maximize CDM growth. 
Since CDMs might be one day implanted into humans, it was also desirable to eliminate 
any non-human components. Chemically-defined media have been formulated for 
fibroblasts (Bettger et al., 1981; Shipley and Ham, 1983), epidermal cells (Parenteau, 
1994; Vaccariello et al., 1999) and dermal equivalents (Bettger et al., 1981; Shipley and 
Ham, 1983; Parenteau, 1994; Vaccariello et al., 1999), but none of these were designed 
to promote a high synthetic rate in fibroblasts.  
*CDM:  Cell-derived matrix fed with the chemically-defined medium developed 
to induce fibroblasts to synthesize extensive ECM (see Appendix 4). Cells were plated at 
high density on porous inserts and fed with a chemically-defined medium consisting of a 
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base of 3:1 ratio of DMEM (high glucose (4.5g/L); with L-glutamine and sodium 
puryvate, Mediatech) and Ham’s F12 (Invitrogen) with the addition of 5µg/ml insulin, 
5ng/ml selenious acid, 10-4M ethanolamine, 150µg/ml L-ascorbic acid phosphate 
magnesium salt n-hydrate (Wako Pure Chemical), 2.5ng/ml epidermal growth factor 
(EGF, BD Biosciences, in 5µg/ml human serum albumin, EMD Biosciences, San Diego, 
CA), 5ng/ml basic fibroblast growth factor (bFGF, BD Biosciences), 1.0 x 10-7M 
dexamethasone, 2 x 10-10M L-3,3’,5-Triiodothyronine, 4 x 10-3M of Glutamax™ 
(Invitrogen), 1µg/ml Glutathione (reduced), and 1% Penicillin/Streptomycin/ 
Amphotericin B (Invitrogen). (See Appendix 1 for protocol on how to make cell-derived 
matrix.) 
**CDM:  Cell-derived matrix fed with the chemically-defined medium with 
growth factors added to the stock medium at the start of the 3-week experiment (not fresh 
at every feeding). A slight modification to the chemically-defined medium, entailing the 
addition of the growth factors (2.5ng/ml EGF and 5.0ng/ml bFGF) fresh into the entire 
stock medium only at the start of the experiment rather than mixing fresh growth factors 
separately with the stock media every time the samples are fed, was used to study the 
effects of decreasing growth factor concentration over time on the growth and 
development of cell-derived matrix. Growth factors are known to decrease over time in 
wounds (Clark, 1996; Diegelmann and Evans, 2004). An attempt at roughly simulating 
this involved adding growth factors at the start of the experiment and taking advantage of 
the natural loss of growth factor activity in media over time (personal communication 
with BD Biosciences). Alternatively, adding one-tenth the amount of fresh growth factors 
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at each feeding was also attempted; however, the CDM did not grow sufficiently thick to 
perform mechanical testing (data not shown).  
To minimize variability and maximize validity of comparison, the chemically-
defined medium fed CDMs (*CDMs) and the modified chemically-defined medium fed 
CDMs (**CDMs) were grown in an identical fashion alongside the standard serum-
supplemented medium fed CDMs (CDMs), collagen gels (CGs), and fibrin gels (FGs). 
Collagen gels fed with the developed chemically-defined medium (*CGs) and modified 
chemically-defined medium (**CGs) could not be studied because the samples 
contracted into balls within 24 hours after being fed with the chemically-defined medium 
(data not shown). 
 
Mechanical Testing 
After 3 weeks in culture, the samples were exposed to ddH2O for 1h to lyse the 
cells and thus eliminate the contractile forces produced by the fibroblasts, and then 
equilibrated in phosphate buffered saline (PBS, Mediatech) for biomechanical testing. 
The thickness, failure tension, failure strain, and ultimate tensile strength (UTS) of the 
samples were determined by a novel tissue inflation device (Billiar, 2000).  Briefly, this 
device measures the displacement and pressure at which a sample bursts when inflated 
with PBS at a constant rate of 1 ml/min. The sample is circularly clamped at and inflated 
through a 1cm diameter opening, thus causing the sample to form a spherical cap before 
failing. The increasing pressure applied to the sample is measured by an on-board 
pressure transducer (model PX102-025GV, Omega Engineering, Stamford, CT). The 
displacement of the center of the cap is measured with a laser displacement system (LDS-
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080, Keyence, Woodcliff Lake, NJ). The LSD-080 also measures the thickness of each 
sample after being slightly compressed by a small reflective disk (1.3g, 1.3cm diameter) 
for 1 minute. The maximum membrane tension, T, is calculated using the Law of Laplace 
for a spherical membrane: 
T = ½ PR,         (eq. 1) 
where P is the pressure when the tissue bursts and R is the corresponding radius at the 
point of rupture, calculated assuming a spherical cap geometry by: 
   R = (w2 + a2) / 2w,        (eq. 2) 
where a is the radius of the clamp (5mm) and w is the displacement at the center of the 
sample at failure measured by the laser.  
The ultimate tensile strength (UTS) is calculated by: 
 UTS = T / t,         (eq. 3) 
where t is the initial thickness of the specimen before inflation. The actual thickness at 
the time of bursting is less than this value. Thus the calculated UTS (engineering stress) 
is less than the true stress at failure, since the thickness of the specimen decreases as it is 
being inflated.  
The ultimate tensile strength per collagen density (UTS / Collagen Density) is calculated 
by: 
 UTS / Collagen Density = UTS / (Total Collagen / πt(D/2)2) 
       = T / (Total Collagen / π(D/2)2),   (eq. 4) 
where D is the diameter of the constructs (2.4cm). This calculated index represents the 
strength of the constructs normalized per unit of collagen and is independent of the 
thickness of the samples.  
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The failure strain is determined from the equibiaxial strain at the pole estimated from the 
displacement data using the approximate relationship from (Winston et al., 1989): 
Failure Strain = 2/3 (w / a)2 – 2/15 (w / a)4 + 2/35 (w / a)6.     (eq. 5) 
 
Biochemical Analysis 
Following biomechanical testing, the samples were weighed (wet weight), 
lyophilized overnight, and then weighed again (dry weight). Each lyophilized sample was 
solubilized in 1ml pepsin (1 mg/ml in 0.5M acetic acid) and incubated overnight at 20°C 
with rotation. This extraction step was repeated to achieve complete extraction of the 
pepsin and acid soluble fraction of collagen. The samples were then centrifuged at 14000 
rpm for 1 hour at 15°C, and the supernatant was combined with samples from the first 
extraction and used for determining non-cross-linked collagen content using the Sircol™ 
Assay (Biocolor, Belfast, N. Ireland). The Sircol™ Assay quantified the content of intact 
collagen monomers in the solution, and does not detect degraded collagen (these amounts 
were 5-10% of the actual collagen content (data not shown) determined by a 
hydroxyproline assay (see methods below)). Total non-collagenous protein content of 
each extract was determined with the Tp-Blue™ Total Protein Assay (Biocolor) using 
Coomassie brilliant blue G (Bradford, 1976). Total protein content was obtained by 
adding this value to the total amount of collagen obtained for each sample. The remaining 
pellets were digested with Proteinase K (Invitrogen), 50µg in 500µl solution of 10mM 
EDTA and 0.1 M sodium phosphate (pH 6.5)(Fisher) overnight at 60°C. A 100µl aliquot 
of the digest was used for determining sulfated glycosaminoglycan and proteoglycan 
content (which does not include hyaluronic acid) with the Blycan™ Assay (Biocolor). A 
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10µl aliquot of the digest was then used to determine DNA content, and thus cell number 
(assuming 8pg of DNA per cell), with Hoechst 33258 dye (Amersham Biosciences, 
Piscataway, NJ) on a DyNA Quant 200 fluorometer (Amersham Biosciences). 100-200 µl 
aliquots of the Proteinase K digests were used to determine the non-acid and pepsin 
extractable collagen content (insoluble collagen fraction) with a hydroxyproline assay. 
The hydroxyproline assay was based on the methods of Edwards and O'Brien (1980) and 
consists of hydrolyzing each sample in 6.0 M HCl for 16 hours at 110oC, followed by 
drying of the samples under vacuum, reconstituting to 2.0ml with assay buffer (consisting 
of 5g/l citric acid, 1.2ml/l glacial acetic acid (EMD Chemicals, Gibbstown, NJ), 12g/l 
sodium acetate (VWR, Bridgeport, NJ), and 3.4g/l sodium hydroxide (VWR)), mixing 
with 1.0ml of Chloramine-T reagent (made from 62mM chloramine-T solution (VWR) in 
20.7% ddH2O, 26% n-propanol (VWR) and 53.3% of assay buffer) for 20 minutes at 
room temperature, adding 1.0ml of freshly prepared dimethylaminobenzaldehyde reagent 
(made from 15g p-dimethylaminobenzaldehyde in 60ml of n-propanol (VWR) and 26ml 
of 60% perchloric acid (VWR)) and incubating each sample at 60oC for 15 minutes, 
cooling each sample in tap water for 5 minutes, and measuring the absorbance of each 
sample at 550 nm within 45 minutes. Absorbance readings were correlated with collagen 
amount using a standard curve and a conversion factor of 10µg collagen to 1µg 4-
hydroxyproline. The standard curve was created and the conversion factor determined 
with known amounts of Trans-4-hydroxy-L-proline and rat tail type I collagen. 
(See Appendix 3 for complete protocol.) 
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Histology and Transmission Electron Microscopy 
One sample from each group was prepared for histological evaluation by fixing in 
10% zinc formalin (VWR) for 1 hour, followed by washing and storing in 4°C ethanol. 
The samples were embedded onto paraffin blocks, sectioned into 10µm thick sections, 
and stained with hematoxylin and eosin (H&E). The stained sections were imaged and 
photographed at 200x with a Nikon Eclipse E600 microscope and Spot digital camera 
(Diagnostic Instruments, Sterling Heights, MI). 
One sample from each group (except **CDM) was fixed for transmission electron 
microscopy (tEM) according to the methods of Gibson and Lang (1979). Briefly, the 
samples were fixed in 2% glutaraldehyde for 1 hour, rinsed 3 times in sodium cacodylate 
buffer, fixed in osmium tetroxide for 10 minutes, and dehydrated in 10 minute ethanol 
(VWR) steps followed by two washes in propylene oxide (all from Electron Microscopy 
Sciences, Hatfield, PA). The samples were then embedded in epon-araldite resin 
(Electron Microscopy Sciences) according to the methods of Karnovsky (1965). Briefly, 
the samples were embedded in a 1:1 ratio of propylene oxide to Epon Araldite for 2 
hours, followed by embedding in 100% Epon Araldite for 3 hours, and then transferring 
each sample to embedding molds with fresh 100% Epon Araldite and cured in a 60°C 
oven overnight. 60-90nm gold- and silver-colored sections were stained for 5 minutes 
with urinyl acetate saturated in 50% ethanol, followed by staining for 20 minutes in lead 
citrate according to the methods of Venable and Coggesmall (1965). The stained sections 
from each of the samples were then imaged with a ZEISS electron microscope for 
observation of cell, collagen, and ECM morphology. The average collagen fibril diameter 
and density were calculated from the average measured diameters and number of 
Jan-Eric W. Ahlfors 
  18
collagen fibrils per square micrometer from 5 randomly chosen fields taken at high 
magnification (57,000X or 88,000X). The collagen diameters were measured at the 
thinnest point of cross-sectioned collagen fibrils with a 5x magnified ruler. If a randomly 
chosen field fell on a grid, then another field continued to be randomly chosen until it fell 
solely on the sample. 
 
Statistics 
 Error bars indicate one standard deviation in all figures. Statistical differences 
between groups were determined using ANOVA with Tukey HSD post hoc analysis 
(SPSS, Inc., Chicago, IL).  Differences were considered significant with p<0.05 (see 
Appendix 5 for complete analysis). Linear regression including all the samples was 
performed with Tension and Failure Strain as the dependent variables and Total Protein, 
Total Collagen, Non-Acid and Pepsin Extractable Collagen Fraction, Total Proteoglycans 
and Glycosaminoglycans, and Cell Number as the independent variables, and the 
adjusted R2-values were obtained for determining the degree of association between the 
independent and dependent variables (SPSS, Inc.). 
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Results 
 
All samples were sufficiently thick and strong at the end of the 3-week culture 
period to be handleable and clamped in the mechanical testing device. All samples burst 
in the center. The collagen and fibrin gels started out at a thickness of 2.2 mm (1ml on a 
24mm diameter well) and contracted to a thickness 83 ± 5 µm and 218 ± 5 µm, 
respectively, as the cells reorganized the initially sparse protein gels, whereas the CDMs 
started out as slightly more than a single cell layer thick and grew to 125 ± 6 µm during 
the 3-week period. The CDMs were substantially stronger (UTS = 223 ± 9 kPa) than the 
collagen gels (169 ± 43 kPa) and significantly stronger than the fibrin gels (133 ± 11 kPa, 
p<0.01).  The collagen gels were significantly less extensible than the fibrin gels.   
The results from the mechanical and biochemical analyses of CDMs, collagen 
gels and fibrin gels are summarized in Table 1. The net total protein synthesized by the 
CDMs was significantly more (1.25 ± 0.06 mg) than the net increase in total protein in 
the collagen gels (0.08 ± 0.03 mg, p<0.02) and fibrin gels (0.58 ± 0.04 mg, p<0.05). 
Collagen was a major constituent of the total amount of protein. Observation by 
transmission electron microscopy (tEM) revealed that the diameter of the collagen fibrils 
in the CDMs, collagen gels and fibrin gels were 46 ± 5 nm, 52 ± 10 nm and 47 ± 5 nm, 
respectively, while the collagen density within 3µm around the cell surface was 
significantly greater for the CDMs (79 ± 2 fibrils/µm2) and collagen gels (81 ± 4 
fibrils/µm2) than for the fibrin gels (28 ± 4 fibrils/µm2, p<0.01). Although most of the 
collagen in the collagen gel consisted of large, approximately 56 nm diameter fibrils, 
there was a small presence of approximately 46 nm diameter fibrils; presumably newly 
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synthesized collagen (Fig. 4), indicating that some of the original collagen in the gel had 
been degraded since the total amount of collagen in the collagen gels remained 
unchanged over the 3-week period. The CDMs had a significantly (p<0.01) greater 
fraction of non-acid and pepsin extractable collagen (insoluble collagen fraction) than the 
collagen and fibrin gels. The UTS / Collagen Density was significantly greater (14.5 ± 
1.1 kPa/mg/cm3) for the CDMs than the collagen gels (6.4 ± 1.9 kPa/mg/cm3, p<0.01). 
The high value of UTS / Collagen Density for the fibrin gels (25.9 ± 2.4 kPa/mg/cm3) 
appears to be due to ECM proteins other than collagen, such as fibrin, in the gel.  
 
Table 1. Results from mechanical and biochemical analysis of cell-derived matrices 
(CDMs), collagen gels and fibrin gels containing human foreskin fibroblasts.  Numbers 
indicate mean +/- SD.  Numbers in parentheses indicate approximate initial amount. 
Collagen fibril diameters and densities were measured in proximity to cell surfaces.  
 Collagen gel Fibrin gel CDM 
Ultimate Tensile Strength 168.5 ± 43.1 kPa 133.2 ± 10.6 kPa 223.2 ± 9 kPa 
Thickness 83 ± 5 µm 
(2,220 µm) 
218 ± 5 µm 
(2,220 µm) 
125 ± 6 µm 
(~30 µm) 
Failure Strain 0.13 ± 0.02 0.21 ± 0.03 0.18 ± 0.03 
Total Protein 1.08 ± 0.03 mg 
(1.0 mg) 
1.58 ± 0.04 mg 
(1.0 mg) 
1.25 ± 0.06 mg 
Total Collagen 0.99 ± 0.02 mg 
(1.0 mg) 
0.51 ± 0.03 mg 0.85 ± 0.03 mg 
Insoluble Collagen Fraction 1.5 ± 0.1 % 1.3 ± 0.1 % 2.3 ± 0.2 % 
Collagen Density 26.5 ± 1.5 mg/cm3 5.2 ± 0.2 mg/cm3 15.1 ± 0.9 mg/cm3 
UTS / Collagen Density 6.4 ± 1.9 
kPa/mg/cm3 
25.9 ± 2.4 
kPa/mg/cm3 
14.5 ± 1.1 
kPa/mg/cm3 
Collagen Fibril Diameter 52 ± 10 nm 47 ± 5 nm 46 ± 5 nm 
Collagen Fibril Density 81 ± 4 fibrils/µm2 28 ± 4 
fibrils/µm2 
79 ± 2 fibrils/µm2 
Proteoglycans & 
Glycosaminoglycans 
 
38.4 ± 0.7 µg 
 
45.4 ± 0.9 µg 
 
31.3 ± 0.5 µg 
Wet Weight / Dry Weight 16.4 ± 0.6 20.1 ± 0.4 13.0 ± 0.5 
Cell Number 2.8 ± 0.1 million 
(2.0 million) 
4.0 ± 0.1 million 
(2.0 million) 
2.8 ± 0.1 million 
(2.0 million) 
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The *CDMs and **CDMs were also grown in parallel next to the CDMs, collagen 
gels and fibrin gels in the same 6-well plates, but they were fed with a chemically-defined 
medium instead of a serum-supplemented medium. To compare the effects of the 
chemically-defined medium on matrix growth, the *CDMs and **CDMs were compared 
to CDMs (that were fed with the standard serum-supplemented medium). The 
chemically-defined medium, on the other hand, caused the contractile forces within the 
collagen gels to become so great that they detached from the wells and contracted into 
themselves, preventing a comparison of the effects of the chemically-defined medium 
and the serum-supplemented medium on the development of gels.  
The collagen in the cell-derived matrices organized into several alternating layers 
that were at right-angles to each other, resembling native soft connective tissue (see 
Appendix 6). Cells produced a more than 3 times thicker matrix in the chemically-
defined medium (*CDMs at 395 ± 6 µm) than in the standard serum-supplemented 
medium (CDMs at 125 ± 6 µm). One-time addition of growth factors at the start of the 3-
week period resulted in a significantly thinner matrix (**CDMs at 225 ± 7 µm) than 
when the growth factors were added fresh at every feeding. The thicknesses correlated 
with total protein content (adjusted R2=0.900), which in turn correlated with total cell 
number (adjusted R2=0.874). However, the **CDMs had significantly more total 
collagen than *CDMs, although the *CDMs had almost twice as much total protein as the 
**CDMs. The **CDMs were almost twice as strong as the *CDMs (**CDMs at 697 ± 36 
kPa significantly stronger (p<0.01) than *CDMs at 315 ± 7 kPa), which in turn were 
significantly stronger than the CDMs (UTS = 223 ± 9 kPa, p<0.01) (see Table 3). Cell-
derived matrices grown for longer periods of time further increased in thickness and 
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strength (data not shown). For comparison, the thickness of the samples obtained from 
histological sections were 110µm, 465µm, and 240µm, for CDM, *CDM, and **CDM, 
respectively (see figure 1). The failure strains for the *CDMs and **CDMs were almost 
twice as great as for the CDMs.  
The results from the mechanical and biochemical analysis of CDMs, *CDMs and 
**CDMs are summarized in Table 2. The CDMs and **CDMs had about a 2x greater 
fraction of their total protein as collagen than *CDMs. Observation by transmission 
electron microscopy (tEM) revealed that CDMs and *CDMs had approximately the same 
diameter collagen fibrils at 46 ± 5 nm and 48 ± 5 nm, and the same collagen density at 79 
± 2 fibrils/µm2 and 80 ± 2 fibrils/µm2, respectively, measured within 3µm around the cell 
surface. The *CDMs and **CDMs had more than a five times greater fraction of non-
acid and pepsin extractable collagen (insoluble collagen fraction) than the CDMs. The 
UTS / Collagen Density reflected the high insoluble collagen fraction values and was 
significantly greater for the *CDMs (40.3 ± 0.4 kPa/mg/cm3) and **CDMs (40.0 ± 1.9 
kPa/mg/cm3) than for the CDMs (14.5 ± 1.1 kPa/mg/cm3, p<0.01).  
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Table 2. Results from mechanical and biochemical analysis of CDMs, *CDMs and 
**CDMs.  Numbers indicate mean +/- SD.  Numbers in parentheses indicate approximate 
initial amount. Collagen fibril diameters and densities were measured in proximity to cell 
surfaces. Standard serum-supplemented medium fed CDM data from Table 1 reported for 
comparison. 
 CDM *CDM **CDM 
Ultimate Tensile Strength 223.2 ± 9 kPa 314.5 ± 7.2 kPa 697.1 ± 36.1 kPa 
Thickness 125 ± 6 µm 
(~30 µm) 
395 ± 6 µm 
(~30 µm) 
225 ± 7 µm 
(~30 µm) 
Failure Strain 0.18 ± 0.03 0.33 ± 0.03 0.31 ± 0.06 
Total Protein 1.25 ± 0.06 mg 4.40 ± 0.08 mg 2.65 ± 0.07 mg 
Total Collagen 0.85 ± 0.03 mg 1.40 ± 0.04 mg 1.78 ± 0.06 mg 
Insoluble Collagen Fraction 2.3 ± 0.2 % 12.8 ± 0.5 % 13.1 ± 0.3 % 
Collagen Density 15.1 ± 0.9 mg/cm3 7.8 ± 0.2 mg/cm3 17.4 ± 0.1 mg/cm3
UTS / Collagen Density 14.5 ± 1.1 
kPa/mg/cm3 
40.3 ± 0.4 
kPa/mg/cm3 
40.0 ± 1.9 
kPa/mg/cm3 
Collagen Fibril Diameter 46 ± 5 nm 48 ± 5 nm - 
Collagen Fibril Density 79 ± 2 fibrils/µm2 80 ± 2 fibrils/µm2 - 
Proteoglycans & 
Glycosaminoglycans 
 
31.3 ± 0.5 µg 
 
64.3 ± 0.6 µg 
 
38.4 ± 0.4 µg 
Wet Weight / Dry Weight 13.0 ± 0.5 19.5 ± 0.2 20.3 ± 0.6 
Cell Number 2.8 ± 0.1 million 
(2.0 million) 
6.1 ± 0.1 million 
(2.0 million) 
3.6 ± 0.1 million 
(2.0 million) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1. Hematoxylin and Eosin (H&E) stained sections. Thickness measured by digital 
image analysis: Cell-derived matrices (CDMs) were 110µm thick, collagen gels (CGs) 
were 84µm thick, fibrin gels (FGs) were 230µm thick, *CDMs were 465µm thick, and 
**CDMs were 240µm thick. All micrographs taken at 200x. Scale bars = 100µm. 
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Figure 2. Results from biomechanical and biochemical analysis. All types of the cell-
derived matrices were stronger than collagen gels (CG) and fibrin gels (FG). *CDMs and 
**CDMs were significantly thicker and contained far more total protein than their serum-
supplemented companions (CDMs, collagen gels and fibrin gels), but had only half the 
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percentage of proteoglycans and glycosaminoglycans. *CDMs and **CDMs also 
contained a significantly higher fraction of non-acid and pepsin extractable collagen 
(insoluble collagen fraction), and were stronger per microgram of collagen 
(UTS/Collagen Density) than collagen gels or fibrin gels. CDMs were more than twice as 
strong as collagen gels per microgram of collagen, indicating the possibility that the 
collagen in the CDMs was more organized for strength than in collagen gels. In addition 
to collagen, a substantial proportion of the strength of *CDMs and fibrin gels was also 
due to other ECM proteins. *CDMs and **CDMs were significantly more extensible than 
CDMs, collagen gels and fibrin gels. 
 
 
 
Table 3. Statistical comparison between each group of specimens. *CDMs were 
significantly different than CDMs and collagen gels in all parameters tested. *CDMs and 
**CDMs had the least number of significantly different parameters than any other pair of 
groups. Statistical differences between groups were determined using ANOVA with 
Tukey HSD post hoc analysis, with differences with p<0.05 being considered significant. 
The same 12 parameter shown in Figure 2 were used. The parameters between groups 
that were NOT significantly different from each other are indicated with a letter.  
Key: a = thickness, b = total protein, c = cell number, d = tension, e = ultimate tensile strength (UTS), f = 
failure strain, g = total collagen, h = % collagen, i = fraction of non-acid and pepsin extractable collagen, j 
= total proteoglycans and glycosaminoglycans, k = % proteoglycans and glycosaminoglycans, l = UTS / 
Collagen Density. 
 Collagen Gel Fibrin Gel CDM *CDM **CDM 
Collagen Gel - e,i c,e,f  j 
Fibrin Gel e,i - d,f h a 
CDM c,e,f d,f -  h 
*CDM  h  - f,i,k,l 
**CDM j a h f,i,k.l - 
 
 
 
 
The results from linear regressions of all the samples with Tension as the 
dependent variable and Total Protein Amount, Total Collagen Amount, Non-Acid and 
Pepsin Extractable Collagen Fraction, Total Proteoglycan and Glycosaminoglycan 
Amount, and Cell Number as the independent variables are shown in Table 4, along with 
the adjusted R2-values.  The adjusted R2-value indicates the fraction of the total variance 
in “Tension” explained by the regression equation. The adjusted R2-values are always 
less than the coefficient of determination R2.  These results indicate that there is a high 
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degree of association between the “Non-Acid and Pepsin Extractable Collagen Fraction” 
and “Tension” for collagen gels, fibrin gels, and cell-derived matrices (adjusted R2 = 
0.977). With the addition of the “Total Collagen Amount” independent variable, the 
adjusted R2 value increases to 0.992. Further addition of the “Total Protein Amount” 
independent variable increases the adjusted R2-value by an insignificant amount to 0.993. 
A scatterplot of Tension vs. Total Collagen Amount and Non-Acid and Pepsin 
Extractable Collagen Fraction is shown in Figure 3. Since the area of all the samples were 
essentially identical, and if each variable was divided by the thickness of the samples, the 
adjusted R2-values in Table 4 would be the same for UTS (UTS = Tension / thickness of 
sample) as the dependent variable and Protein Density, Collagen Density, Non-Acid and 
Pepsin Extractable Collagen Density, Proteoglycan and Glycosaminoglycan Density, and 
Cell Density as the independent variables (see table 5).  
 
 
Table 4. Adjusted R2-values indicating the fraction of the total variance in Tension of the 
collagen gel, fibrin gel, and cell-derived matrix samples explained by the Total Protein 
Amount, Total Collagen Amount, Non-Acid and Pepsin Extractable Collagen Fraction, 
Total Proteoglycan and Glycosaminoglycan Amount, and Cell Number of the samples.  
Columns with an asterix (*) indicate that the adjusted R2-value given in that column have 
those independent variables added to them. 
Independent Variables: Tension (dependent variable) 
Total Protein Amount (mg) 0.681 0.857   0.977 0.993
Total Collagen Amount (mg) 0.713 * 0.992   * 
Non-Acid and Pepsin Extractable Collagen Fraction (mg) 0.977   * * * 
Total Proteoglycan and Glycosaminoglycan Amount (µg) 0.214         
Cell Number (Million) 0.355         
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Figure 3. Scatter Plot of Tension vs. Total Collagen Amount and Non-Acid and Pepsin 
Extractable Collagen Fraction. Adjusted R2-value = 0.992. Output from SPSS 12.0 for 
Windows (SPSS, Inc., Chicago, IL).   
 
 
 
 
Table 5. Adjusted R2-values indicating the fraction of the total variance in Tension of the 
collagen gel, fibrin gel, and cell-derived matrix samples explained by the Protein Density, 
Collagen Density, Non-Acid and Pepsin Extractable Collagen Density, Proteoglycan and 
Glycosaminoglycan Density, and Cell Density of the samples.  Columns with an asterix 
(*) indicate that the adjusted R2-value given in that column have those independent 
variables added to them. 
Independent Variables:
Protein Density (mg) 0.681 0.857 0.977 0.993
Collagen Density (mg) 0.713 * 0.992 *
Non-Acid and Pepsin Extractable Collagen Density (mg) 0.977 * * *
Proteoglycan and Glycosaminoglycan Density (µg) 0.214
Cell Density (Million) 0.355
UTS (dependent variable)
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The results from linear regressions of all the samples with Failure Strain as the 
dependent variable and Total Protein Amount, Total Collagen Amount, Non-Acid and 
Pepsin Extractable Collagen Fraction, Total Proteoglycan and Glycosaminoglycan 
Amount, and Cell Number as the independent variables are shown in Table 6, along with 
the adjusted R2-values.  The adjusted R2-value indicates the fraction of the total variance 
in the “Failure Strain” explained by the regression equation. These results indicate that 
there is some degree of association between the “Failure Strain” and “Total Protein” 
(adjusted R2 = 0.742) or “Non-Acid and Pepsin Extractable Collagen Fraction” (adjusted 
R2 = 0.709) for collagen gels, fibrin gels, and cell-derived matrices. Together, these two 
independent variables results in an adjusted R2 = 0.787. With the addition of the “Total 
Collagen Amount” independent variable to the “Non-Acid and Pepsin Extractable 
Collagen Fraction”, an adjusted R2 = 0.884 is obtained. Conversely, the independent 
variables “Non-Acid and Pepsin Extractable Collagen Fraction”, “Total Proteogycan and 
Glycosaminoglycan Amount” and “Cell Number” together results in an adjusted R2-value 
of 0.864. A scatterplot of Failure Strain vs. Total Collagen Amount and Non-Acid and 
Pepsin Extractable Collagen Fraction is shown in Figure 4. 
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Table 6. Adjusted R2-values indicating the fraction of the total variance in Failure Strain 
of the collagen gel, fibrin gel, and cell-derived matrix samples explained by the Total 
Protein Amount, Total Collagen Amount, Non-Acid and Pepsin Extractable Collagen 
Fraction, Total Proteoglycan and Glycosaminoglycan Amount, and Cell Number of the 
samples.  Columns with an asterix (*) indicate that the adjusted R2-value given in that 
column have those independent variables added to them. 
Independent Variables:
Total Protein Amount (mg) 0.742 0.787 0.761 0.797
Total Collagen Amount (mg) 0.332 0.884
Non-Acid and Pepsin Extractable Collagen Fraction (mg) 0.709 * 0.823 * 0.775 0.864
Total Proteoglycan and Glycosaminoglycan Amount (µg) 0.396 * * * *
Cell Number (Million) 0.583 * * *
Failure Strain (dependent variable)
 
 
 
 
 
Figure 4. Scatter Plot of Failure Strain vs. Total Collagen Amount and Non-Acid and 
Pepsin Extractable Collagen Fraction. Adjusted R2-value = 0.884. Output from SPSS 
12.0 for Windows (SPSS, Inc., Chicago, IL).   
  
 
 
 
 
 
Figure 5. Sample morphology observed with tEM. The fibroblasts within the *CDM 
appeared to be slightly larger than in the other samples. Fibrin gels had a cell density that 
was significantly higher than in the other samples. All micrographs taken at 3,000x. Scale 
bar = 10µm. 
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Figure 6. Distribution of collagen fibrils. CDMs, collagen gels, and *CDMs had a more 
than 2.5 times greater density of collagen fibrils around the cell surface at around 80 
fibrils/µm2 than fibrin gels at 28 fibrils/µm2. The collagen fibrils of the cell-derived 
matrices appeared more parallel and to consist of more parallel alternating layers than 
any of the other groups. The collagen fibrils of the collagen gels appeared somewhat 
parallel but consisted of only a few alternating layers, while the collagen fibrils of the 
fibrin gels appeared only parallel in small regions of the ECM. The collagen gels had a 
large majority of collagen fibrils about 56 nm in diameter due to the collagen gel, and a 
small number of collagen fibrils about 46 nm in diameter that had presumably been 
secreted by the fibroblasts. All micrographs taken at 12,000x. Scale bar = 1µm. 
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Discussion 
 
The data from the present study suggest that tissue-equivalents could be grown 
stronger and thicker when they are self-produced – in other words, when the cells are 
allowed to grow and develop their own mechanical environment rather than being 
supplied with a mechanical environment as in gels. To gather more insight into the 
differences between fibroblast-populated collagen gels, fibrin gels, and cell-derived 
matrices, it was desirable to reduce experimental variability by growing all groups next to 
each other on the same 6-well plates for 3-weeks, seeded with the same number of cells 
from the same batch, and fed with the same standard serum-supplemented medium at the 
same frequency. While the collagen and fibrin gels contracted more than an order of 
magnitude (2.2 mm to a thickness 83 ± 5 µm and 218 ± 5 µm, respectively) over the 3-
week culture period as the cells reorganized the initially sparse protein gels, the CDMs 
quadrupled in thickness (~30µm to a thickness of 125 ± 6 µm) and were significantly 
stronger (UTS = 223 ± 9 kPa) than the collagen gels (169 ± 43 kPa, p<0.05 LSD) and the 
fibrin gels (133 ± 11 kPa, p<0.01).  The net increase in protein accumulated by the CDMs 
was significantly more (1.25 ± 0.06 mg) than the net increase in protein accumulated by 
the collagen gels (0.08 ± 0.03 mg, p<0.02) and fibrin gels (0.58 ± 0.04 mg, p<0.05).  
The collagen in collagen gels is known to signal embedded fibroblasts to 
drastically slow down their proliferation and synthesis of ECM proteins (Clark, 1996). 
However, the synthesized collagen in the CDMs and fibrin gels (Neidert et al., 2002) did 
not appear to have this effect. The amount of collagen in the CDMs (0.85 ± 0.03 mg) was 
essentially the same as in the collagen gels (0.99 ± 0.02 mg) at the end of the 3-week 
Jan-Eric W. Ahlfors 
  34
culture period. CDMs also contained far more non-collagenous protein (0.40 ± 0.03 mg) 
than the collagen gels (0.09 ± 0.01 mg, p<0.01). The lack of any collagen in the fibrin 
gels at the start of the culture did not present any inhibitory signal towards collagen 
synthesis as in the case of the collagen gels, but fibrin is known to downregulate 
fibroblast procollagen mRNA (Clark, 1996) which possibly explains the observation that 
the fibroblasts within the fibrin gel ended up synthesizing only half as much collagen 
(0.51 ± 0.03 mg) as the CDMs during the 3 week period. Interestingly, the net total non-
collagenous protein synthesized in the fibrin gels was also very low (0.07 ± 0.01 mg).  
The UTS / Collagen Density was also significantly greater (14.5 ± 1.1 
kPa/mg/cm3) for the CDMs than the collagen gels (6.4 ± 1.9 kPa/mg/cm3, p<0.01). Each 
microgram of collagen in the CDMs was thus more than twice as strong as each 
microgram of collagen in the collagen gels, possibly due to higher collagen cross-link 
density and/or more organized arrangement of collagen in the CDMs. The UTS / 
Collagen Density values correlated with the non-acid and pepsin extractable collagen 
fraction for the CDMs and collagen gels (R2 = 0.925), but not for the fibrin gels (R2 = 
0.109). The high value of UTS / Collagen Density for the fibrin gels (25.9 ± 2.4 
kPa/mg/cm3) appears to be due to ECM proteins other than collagen, such as fibrin, in the 
gel, that contributed substantially to the strength.  
Collagen gels have been studied extensively for the last several decades as in vitro 
wound-healing models, and much effort has gone into developing stronger collagen gels 
for use as tissue equivalents (Grinnell, 2003). Recently, Feng et al. (2003) measured the 
UTS of collagen gels at 250kPa at 10 weeks when allowed to contract freely. Earlier 
development and characterization of tissue equivalents made from collagen gels 
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(ligament-equivalent fibroblast-populated collagen matrices) by Huang et al. (1993) 
resulted in an ultimate tensile strength (UTS) of 140 kPa in 12 weeks when mechanically 
stimulated uniaxially. The cell number tripled in 2 weeks from an initial cell density of 1 
million cells/ml and remained at this cell number for the rest of the period, compared to 
an almost tripling in cell number in 3 weeks for the collagen gels in this study. The total 
weight of the constructs decreased from 12mg at week 1 to 10mg after week 3, while the 
sulfated glycosaminoglycan content increased steadily over the 12 week period. In 
comparison, the total weight of the collagen gels in this study remained fairly constant 
during the 3-week period, and the total sulfated proteoglycan and glycosaminoglycan 
content was 38.4 ± 0.7 µg at the end of the 3-week culture period.  
Recent developments in engineering strong fibrin gels by Neidert et al. (2002) 
with an initial fibrinogen concentration of 3.3 mg/ml and the addition of factors such as 
TGF-β1 and insulin in addition to 10% fetal bovine serum has produced tissue 
equivalents with a tensile strength (UTS) of 240 kPa over a 51 day growth period. These 
fibrin gels contracted 1500 ± 115µm to 200 ± 72µm within 4 days, and contained about 
100µg/cm2 of collagen at day 21 and about 230µg/cm2 of collagen at day 51 which 
represented 33 ± 5.4 % of the total dry weight. The fibrin gels in this study had similar 
results and contained 113 ± 10 µg/cm2 collagen at day 21 which represented 32.2 ± 1.2 % 
of the total protein in the constructs. Neidert et al. (2002) also found that the UTS of 
fibrin gels are correlated to the total collagen amount in the constructs (R2 = 0.7686 at 
day 21), while this study found that the UTS correlated to the collagen density (R2 = 
0.733 at day 21) not just in fibrin gels but also in collagen gels and cell-derived matrices. 
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However, the UTS was found to correlate even more closely to the non-acid and pepsin 
extractable collagen fraction (R2 = 0.993) in all of these specimens.  
The cell-derived matrices cultured with the standard serum-supplemented medium 
had similar, but higher, values for thickness and amount of collagen (125 ± 6 µm; 0.189 ± 
0.007 mg/cm2 collagen in 3 weeks) as the self-produced matrices produced by Grinnell et 
al. (1989)) that grew multiple cell layers thick with 0.118 ± 2 mg/cm2 collagen in 5 
weeks. These differences might be due to the much higher starting cell density of 4.4x105 
cells/cm2 wells (compared to 5x104 cells/cm2 wells by Grinnell et al. (1989), feeding of 
the samples every other day, the use of porous inserts, and 80% greater concentration of 
L-ascorbate, in the more stable form of L-ascorbic acid phosphate magnesium salt n-
hydrate (1 week stability vs. 24h for L-ascorbate).  Ishikawa et al. (1997) have grown 
cell-derived matrices that synthesized 0.327 ± 0.66 mg collagen in 4 weeks. L'Heureux et 
al. (1998) have made matrices of 120µm in thickness in 4 weeks. Clark et al. (1997), on 
the other hand, have produced matrices that were 3-5 cell layers thick in 2 weeks, but 8-
16 cell layers thick in 2 weeks when TGF-β1 was added into the serum-supplemented 
medium. 
As with many native connective tissues, much of the strength of these cultured 
tissues can be attributed to the collagen density (Hukins, 1982; Roeder et al., 2002). 
However, while the CDMs had 68.2 ± 1.1 % of their total protein as collagen, they were 
significantly weaker (UTS = 223.2 ± 9.0 kPa, p<0.01) than the cell-derived matrices 
cultured with the chemically-defined medium, or *CDMs (UTS = 314.5 ± 7.2 kPa) that 
had only 31.8 ± 0.5 % of their total protein as collagen and the **CDMs (UTS = 697.1 ± 
36.1 kPa) that had 67.0 ± 0.6 % of their total protein as collagen. The collagen gels, in 
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turn, with 91.8 ± 1.0 % of their total ECM proteins as collagen were even weaker than 
this (UTS = 168.5 ± 43.1, p<0.05). The UTS / Collagen Density values for the *CDMs 
and **CDMs (40.3 ± 0.4 kPa/mg/cm3 and 40.0 ± 1.9 kPa/mg/cm3, respectively) were 
thus significantly higher than for the CDMs (14.5 ± 1.1 kPa/mg/cm3). This difference 
could be due to the high tensile strength of collagen being largely attributable to the 
presence of intra-molecular covalent cross-links between the collagen fibrils (Parry, 
1988). The non-acid and pepsin extractable collagen fraction was closely correlated to the 
UTS / Collagen Density values for all these groups (see Table 3). The non-acid and 
pepsin extractable collagen fraction might thus represent collagen cross-links in these 
samples or some other property leading to significant stability of the collagen fibrils and 
strengthening of the matrix. Strength also increases with increasing collagen fibril 
diameter and density (which typically range from 20 – 120 nm in diameter in native 
tissue) (Hukins, 1982; Huang et al., 1993; Christiansen et al., 2000; Roeder et al., 2002), 
but the collagen fibril diameters and densities for all these samples were essentially the 
same, so this does not appear to be a significantly contributing factor to the differences in 
strength. 
Although the collagen gels had by far the greatest percentage of collagen, the 
largest collagen fibril diameters and were allowed to be contracted by the fibroblasts in 
order to increase their strength (Huang et al., 1993; Seliktar et al., 2000; Roeder et al., 
2002; Feng et al., 2003), they were substantially weaker than the CDMs grown under 
identical conditions. The ratio of UTS to Collagen Density of the collagen gels was less 
than half the value of the CDMs. This might be due to the collagen being more organized 
for strength in the CDMs, 50% greater fraction of non-acid and pepsin extractable 
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collagen, and larger amounts of other supporting ECM proteins, including the possibility 
of fibronectin. (Gillery et al., 1986; Klueh et al., 2001; Gildner and Hocking, 2003) have 
shown that strength increases with the addition of fibronectin which increases actin 
organization and regulates the composition of the ECM. For example, Gildner and 
Hocking (2003) have shown that fibronectin induces a 5-fold increase in the ultimate 
tensile strength of collagen gels.  
 
The present data also suggest that serum-free media can be developed that induce 
fibroblasts to produce a stronger and thicker ECM. When cell-derived matrices were fed 
with the chemically-defined medium, they grew significantly thicker and stronger than 
their serum-supplemented counterparts. When collagen gels were fed with the 
chemically-defined medium, the contractile forces within the collagen gels became so 
great that they detached from the wells and contracted into themselves within 24h of 
feeding them with the chemically-defined medium. The reason for the contraction of the 
collagen gels when fed with the chemically-defined medium is the subject of further 
studies. Apart from the necessary components of insulin, selenious acid and a lipid 
precursor (ethanolamine, in this case) in serum-free media (Freshney, 2000) (these 
components are present in serum), the chemically-defined medium was similar to the 
serum-supplemented medium (less the serum) except for the addition of basic fibroblast 
growth factor (bFGF), epidermal growth factor (EGF), dexamethasone and L-3,3’,5-
Triiodothyronine. The addition of these relatively few components (and the lack of the 
numerous other components present in serum), resulted in a doubling (**CDMs) or 
tripling (*CDMs) in thickness and a 40% (*CDMs) to 210% (**CDMs) increase in the 
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ultimate tensile strength over identical standard serum-supplemented samples. It also 
resulted in a doubling of the failure strain, a quadrupling of the proliferation rate, and a 
quintupling of the fraction of non-acid and pepsin extractable collagen. These large 
differences could also be as a result of certain components in fetal bovine serum (FBS) 
having an inhibitory role on the proliferative and synthetic rate of fibroblasts.  
Epidermal growth factor (EGF) was added since it has been shown to stimulate 
the growth and production of non-collagenous proteins and other ECM components such 
as proteoglycans and glycosaminoglycans (Kurata and Hata, 1991) that contribute to the 
mass and thickness of cell-derived matrices. Basic fibroblast growth factor (bFGF), on 
the other hand, plays an important role in normal tissue repair and wound healing, and is 
a potent mitogenic and chemotactic factor for fibroblasts, regulating proliferation and 
extracellular matrix (ECM) production by these cells (Milewski et al., 1998; Aktas and 
Kayton, 2000), and was found to increase the strength and thickness of cell-derived 
matrices in pilot tests. The major reason for the addition of the growth factors into the 
chemically-defined medium was to stimulate the production of numerous non-
collagenous ECM proteins in addition to collagen (Kurata and Hata, 1991) in order to 
produce tissue that might more closely resemble native soft connective tissue. L-
ascorbate was added since it has been found to significantly increase ECM synthesis by 
upregulating the expression of proalpha(1)(I) and proalpha(2)(I) collagen (Grinnell et al., 
1989; Hata and Senoo, 1989; Huang et al., 1993; Kurata et al., 1993; Girton et al., 2000; 
Hoerstrup et al., 2000; Laplante et al., 2001; Pouliot et al., 2002). Since L-ascorbate 
breaks down within 24h in culture, a more stable form (L-ascorbic acid phosphate 
magnesium salt n-hydrate) with a more than one week stability in culture was used 
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(Ishikawa et al., 1997). Ishikawa et al. (1997) found the optimum concentration of this 
form of L-ascorbate to be 1mM for fibroblast cultures; however, half of this amount, 
150µg/ml (519mM), was found to results in a more desirable combination of strength and 
thickness for the cell-derived matrices in pilot tests. Dexamethasone was added since it 
has been shown to significantly increase fibroblast cell proliferation in serum-free media 
(Bettger et al., 1981; Shipley and Ham, 1983) by upregulating the PDGF-alpha receptor 
mRNA and protein (Warshamana et al., 1998), and to promote actin stress fiber 
formation and increased fibronectin matrix accumulation that aid in the more effective 
organization of the ECM (Zoppi et al., 1998; Brenner et al., 2000). Also, the increase in 
collagenase and stromelysin mRNA by EGF that degrade collagen has been shown to be 
inhibited with the addition of dexamethasone (Delany and Brinckerhoff, 1992). Insulin, 
selenious acid, and a lipid precursor (ethanolamine, in this case) were added since they 
are essential standard components of any serum-free media (Freshney, 2000). Insulin also 
increases the residence time of procollagen mRNA and upregulates latent TGF-β1 
synthesis (Ghahary et al., 1999). Interestingly, transferrin, another essential standard 
component of many serum-free media (Freshney, 2000), was not needed and had no 
effect on the growth or strengthening of cell-derived matrices in pilot studies. Further 
studies would be needed to determine the reason for this. L-3,3’,5-Triiodothyronine was 
added to increase the rate of cell metabolism. Due to the high synthetic rate of the 
fibroblasts, extra L-glutamine, which is an energy carbon source for nucleic acid 
synthesis, was added in the form of the more stable Glutamax™ that does not easily 
degrade to ammonia, a compound that adversely affects cell cultures. An antioxidant 
(glutathione (reduced)) was added to prevent oxidative stress in the cells. Most of these 
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components were added only after they had been determined to either significantly 
increase the strength or thickness of cell-derived matrices in pilot studies. The near-
optimum concentrations of these components for producing the best combination of 
increased strength and thickness were determined separately in preliminary studies (data 
not shown), although a full combinatorial media optimization study was beyond the 
scope of this study. 
The much higher strength of the **CDMs compared to the *CDMs appears to 
have resulted from the lowered concentration of growth factors (bFGF and especially 
EGF) in the feeding media over time.  This effect was not duplicated by adding a low 
concentration of fresh growth factors at every feeding instead (data not shown). It is 
possible that the matrices developed mostly in thickness for the first part of the growth 
period followed by development in strength for the remainder of the growth period, since, 
although EGF stimulates the growth and production of non-collagenous proteins, it 
inhibits the transcription of type 1 collagen genes and high bFGF concentrations favor 
enhanced cell proliferation over enhanced ECM strengthening (Kurata and Hata, 1991). 
Thus a decrease in growth factor concentration over time could increase the strength of 
the ECM by the resulting increase in collagen production. This leads to a hypothesis that 
cell-derived matrices that grow thicker have a greater fraction of proteins and other ECM 
components other than collagen, while cell-derived matrices that grow stronger but 
thinner in the same period of time have a greater fraction of collagen. In this study, 
although the fibroblasts in the *CDMs synthesized significantly more ECM than the 
fibroblasts in the **CDMs, the **CDMs had significantly more total amount of collagen 
than the *CDMs. Further studies would need to be performed to determine if similar 
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results might be obtained if a relatively high concentration of growth factors promoting 
growth is used during the first part of the culture period, followed by a much lower 
concentration of these growth factors and possibly even the addition of growth factors 
that promote strengthening such as TGF-β1. Many growth factors, including bFGF, can 
accumulate and retain their activity for relatively long periods of time within ECM 
(Aktas and Kayton, 2000; Bottaro et al., 2002), and thus some of the growth factors 
might have accumulated in the ECM during the first part of the culture period and used 
later as the matrix developed. The lowered growth factor concentration over time may 
also approximate what occurs naturally in vivo during the wound healing response (Xing 
et al., 2003; Diegelmann and Evans, 2004), where the high concentration of growth 
factors in a fresh clot decreases over time as it is invaded and reconstructed by 
fibroblasts.  
 
The cell-derived matrices produced in this study have potential in being used as 
soft connective tissue substitutes since they are produced solely from cells fed with a 
chemically-defined medium that does not contain any animal components, and they could 
be made strong and thick enough for certain tissue replacement applications within a 
matter of weeks. Tissue substitutes produced solely from fibroblasts have been developed 
by other groups, such as the completely biological human blood vessels developed by 
Auger et al. (L'Heureux et al., 1998; Auger et al., 2000), but these matrices have taken 
several months to grow, are fed with serum, and usually involve stacking several matrices 
together, thus changing some of the self-produced aspects of the matrix. The higher 
thermal and enzymatic stability and mechanical integrity of cell-derived matrices over 
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both collagen and fibrin gels may allow them to retain their structural integrity longer in 
in vivo conditions. Their high strength and stability could allow them to one day be used 
as alternatives to soft connective tissue and load-bearing tissue. Cell-derived matrices 
might also serve as in vitro biological models for the effects of nutritional components 
and pharmaceutical products on the growth and development of soft connective tissue, as 
well as for numerous in vivo conditions and processes such as wound healing, connective 
tissue formation, and development and interaction of different cells and tissues in a soft 
connective tissue environment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jan-Eric W. Ahlfors 
  44
References 
 
Abe, K., Takayanagi, M. and Saito, H. (1990) A comparison of neurotrophic effects of 
epidermal growth factor and basic fibroblast growth factor in primary cultured 
neurons from various regions of fetal rat brain. Jpn J Pharmacol 54(1): 45-51. 
Aktas, G. and Kayton, R. (2000) Ultrastructural immunolocalization of basic fibroblast 
growth factor in fibroblasts and extracellular matrix. Histochem Cell Biol 113(3): 
227-33. 
Auger, F.A., Pouliot, R., Tremblay, N., Guignard, R., Noel, P., Juhasz, J., Germain, L. 
and Goulet, F. (2000) Multistep production of bioengineered skin substitutes: 
sequential modulation of culture conditions. In Vitro Cell Dev Biol Anim 36(2): 
96-103. 
Basu, A., Rodeck, U., Prendergast, G.C. and Howe, C.C. (1999) Loss of insulin-like 
growth factor I receptor-dependent expression of p107 and cyclin A in cells that 
lack the extracellular matrix protein secreted protein acidic and rich in cysteine. 
Cell Growth Differ 10(11): 721-8. 
Bettger, W.J., Boyce, S.T., Walthall, B.J. and Ham, R.G. (1981) Rapid clonal growth and 
serial passage of human diploid fibroblasts in a lipid-enriched synthetic medium 
supplemented with epidermal growth factor, insulin, and dexamethasone. Proc 
Natl Acad Sci U S A 78(9): 5588-92. 
Billiar, K., Odlum, K., Govignon, E., Bachrach, N. and Ronfard, V. (2000) Mechanical 
characterization of the growth and development of a human extracellular matrix. 
Biomedical Engineering Society Annual Fall Meeting, Seattle, WA. 
Jan-Eric W. Ahlfors 
  45
Bottaro, D.P., Liebmann-Vinson, A. and Heidaran, M.A. (2002) Molecular signaling in 
bioengineered tissue microenvironments. Ann N Y Acad Sci 961: 143-53. 
Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
72: 248-54. 
Bradshaw, A.D., Puolakkainen, P., Dasgupta, J., Davidson, J.M., Wight, T.N. and Helene 
Sage, E. (2003) SPARC-null mice display abnormalities in the dermis 
characterized by decreased collagen fibril diameter and reduced tensile strength. J 
Invest Dermatol 120(6): 949-55. 
Brenner, K.A., Corbett, S.A. and Schwarzbauer, J.E. (2000) Regulation of fibronectin 
matrix assembly by activated Ras in transformed cells. Oncogene 19(28): 3156-
63. 
Butt, R.P., Laurent, G.J. and Bishop, J.E. (1995) Collagen production and replication by 
cardiac fibroblasts is enhanced in response to diverse classes of growth factors. 
Eur J Cell Biol 68(3): 330-5. 
Calve, S., Dennis, R., Kosnik, P., Grosh, K. and Arruda, E. (2003) Engineering of 
Funcional Tendon. ASME Summer Bioengineering Conference, Key Biscayne, 
FL, ASME. 
Carlson, E.C., Mamiya, K., Liu, C.Y., Gendron, R.L., Birk, D.E., Funderburgh, J.L. and 
Kao, W.W. (2003) Role of Cys41 in the N-terminal domain of lumican in ex vivo 
collagen fibrillogenesis by cultured corneal stromal cells. Biochem J 369(Pt 3): 
461-8. 
Jan-Eric W. Ahlfors 
  46
Christiansen, D.L., Huang, E.K. and Silver, F.H. (2000) Assembly of type I collagen: 
fusion of fibril subunits and the influence of fibril diameter on mechanical 
properties. Matrix Biol 19(5): 409-20. 
Clark, R.A., McCoy, G.A., Folkvord, J.M. and McPherson, J.M. (1997) TGF-beta 1 
stimulates cultured human fibroblasts to proliferate and produce tissue-like 
fibroplasia: a fibronectin matrix-dependent event. J Cell Physiol 170(1): 69-80. 
Clark, R.A.F. (1996) The molecular and cellular biology of wound repair. New York, 
Plenum Press. 
Delany, A.M. and Brinckerhoff, C.E. (1992) Post-transcriptional regulation of 
collagenase and stromelysin gene expression by epidermal growth factor and 
dexamethasone in cultured human fibroblasts. J Cell Biochem 50(4): 400-10. 
Diegelmann, R.F. and Evans, M.C. (2004) Wound healing: an overview of acute, fibrotic 
and delayed healing. Front Biosci 9: 283-9. 
Edwards, C.A. and O'Brien, W.D., Jr. (1980) Modified assay for determination of 
hydroxyproline in a tissue hydrolyzate. Clin Chim Acta 104(2): 161-7. 
Elsdale, T. and Bard, J. (1972) Collagen substrata for studies on cell behavior. J Cell Biol 
54(3): 626-37. 
Feng, Z., Yamato, M., Akutsu, T., Nakamura, T., Okano, T. and Umezu, M. (2003) 
Investigation on the mechanical properties of contracted collagen gels as a 
scaffold for tissue engineering. Artif Organs 27(1): 84-91. 
Freshney, R.I. (2000) Culture of Animal Cells. New York, Wiley-Liss. 
Jan-Eric W. Ahlfors 
  47
Geesin, J.C., Gordon, J.S. and Berg, R.A. (1993) Regulation of collagen synthesis in 
human dermal fibroblasts by the sodium and magnesium salts of ascorbyl-2-
phosphate. Skin Pharmacol 6(1): 65-71. 
Ghahary, A., Tredget, E.E., Mi, L. and Yang, L. (1999) Cellular response to latent TGF-
beta1 is facilitated by insulin-like growth factor-II/mannose-6-phosphate 
receptors on MS-9 cells. Exp Cell Res 251(1): 111-20. 
Gibson, D. and Lang, F. (1979) Is embryonic Limulus heart really myogenic? American 
Zoologist 19: 39-51. 
Gildner, C.D. and Hocking, D.C. (2003) Fibronectin polymerization enhances the tensile 
mechanical properties of cell-imbedded collagen gels. 2003 Summer 
Bioengineering Conference, Key Biscayne, Florida. 
Gillery, P., Maquart, F.X. and Borel, J.P. (1986) Fibronectin dependence of the 
contraction of collagen lattices by human skin fibroblasts. Experimental cell 
research 167(1): 29-37. 
Girton, T.S., Oegema, T.R., Grassl, E.D., Isenberg, B.C. and Tranquillo, R.T. (2000) 
Mechanisms of stiffening and strengthening in media-equivalents fabricated using 
glycation. Journal of Biomechanical Engineering 122(3): 216-23. 
Gospodarowicz, D., Ferrara, N., Schweigerer, L. and Neufeld, G. (1987) Structural 
characterization and biological functions of fibroblast growth factor. Endocr Rev 
8(2): 95-114. 
Grinnell, F. (1994) Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol 
124(4): 401-4. 
Jan-Eric W. Ahlfors 
  48
Grinnell, F. (2003) Fibroblast biology in three-dimensional collagen matrices. Trends 
Cell Biol 13(5): 264-9. 
Grinnell, F., Fukamizu, H., Pawelek, P. and Nakagawa, S. (1989) Collagen processing, 
crosslinking, and fibril bundle assembly in matrix produced by fibroblasts in long-
term cultures supplemented with ascorbic acid. Exp Cell Res 181(2): 483-491. 
Hata, R. and Senoo, H. (1989) L-ascorbic acid 2-phosphate stimulates collagen 
accumulation, cell proliferation, and formation of a three-dimensional tissuelike 
substance by skin fibroblasts. J Cell Physiol 138(1): 8-16. 
Hoerstrup, S.P., Zund, G., Schnell, A.M., Kolb, S.A., Visjager, J.F., Schoeberlein, A. and 
Turina, M. (2000) Optimized growth conditions for tissue engineering of human 
cardiovascular structures. Int J Artif Organs 23(12): 817-23. 
Hoerstrup, S.P., Zund, G., Ye, Q., Schoeberlein, A., Schmid, A.C. and Turina, M.I. 
(1999) Tissue engineering of a bioprosthetic heart valve: stimulation of 
extracellular matrix assessed by hydroxyproline assay. Asaio J 45(5): 397-402. 
Huang, D., Chang, T.R., Aggarwal, A., Lee, R.C. and Ehrlich, H.P. (1993) Mechanisms 
and dynamics of mechanical strengthening in ligament-equivalent fibroblast-
populated collagen matrices. Annals of Biomedical Engineering 21(3): 289-305. 
Hukins, D.W.L. (1982) Biomechanical properties of collagen. Collagen in Health and 
Disease. Weiss, J.B. and Jayson, M.I.V. Edinburgh, Churchill Livingstone: 49-72. 
Ishikawa, O., Kondo, A., Okada, K., Miyachi, Y. and Furumura, M. (1997) 
Morphological and biochemical analyses on fibroblasts and self-produced 
collagens in a novel three-dimensional culture. Br J Dermatol 136(1): 6-11. 
Jan-Eric W. Ahlfors 
  49
Karnovsky, M.S. (1965) A formaldehyde-glutaraldehyde fixative of high osmolarity for 
use in electron microscopy. Journal of Cell Biology 27: 137A. 
Kessler, D., Dethlefsen, S., Haase, I., Plomann, M., Hirche, F., Krieg, T. and Eckes, B. 
(2001) Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" 
phenotype. J Biol Chem 276(39): 36575-85. 
Klueh, U., Goralnick, S., Bryers, J.D. and Kreutzer, D.L. (2001) Binding and orientation 
of fibronectin on surfaces with collagen-related peptides. Student Research Award 
in the Masters Science Degree Candidate category, 27th annual meeting of the 
Society for Biomaterials, St. Paul, MN, April 24-29, 2001. J Biomed Mater Res 
56(3): 307-23. 
Kondo, H., Matsuda, R. and Yonezawa, Y. (1993) Autonomous migration of human fetal 
skin fibroblasts into a denuded area in a cell monolayer is mediated by basic 
fibroblast growth factor and collagen. In Vitro Cell Dev Biol Anim 29A(12): 929-
35. 
Kurata, S. and Hata, R. (1991) Epidermal growth factor inhibits transcription of type I 
collagen genes and production of type I collagen in cultured human skin 
fibroblasts in the presence and absence of L-ascorbic acid 2-phosphate, a long-
acting vitamin C derivative. J Biol Chem 266(15): 9997-10003. 
Kurata, S., Senoo, H. and Hata, R. (1993) Transcriptional activation of type I collagen 
genes by ascorbic acid 2-phosphate in human skin fibroblasts and its failure in 
cells from a patient with alpha 2(I)-chain-defective Ehlers-Danlos syndrome. Exp 
Cell Res 206(1): 63-71. 
Jan-Eric W. Ahlfors 
  50
Laplante, A.F., Germain, L., Auger, F.A. and Moulin, V. (2001) Mechanisms of wound 
reepithelialization: hints from a tissue-engineered reconstructed skin to long-
standing questions. Faseb J 15(13): 2377-89. 
Leibovitz, A. (1963) Am. J. Hygiene 78: 173. 
L'Heureux, N., Paquet, S., Labbe, R., Germain, L. and Auger, F.A. (1998) A completely 
biological tissue-engineered human blood vessel. Faseb J 12(1): 47-56. 
Milewski, C., Fedorowski, A., Stan, A.C. and Walter, G.F. (1998) [Basic fibroblast 
growth factor (b-FGF) in the perimatrix of cholesteatoma]. Hno 46(9): 804-8. 
Neidert, M.R., J, W.J. and Tranquillo, R.T. (2002) Development and characterization of 
improved tissue engineered valve-equivalents using chemical and mechanical 
signaling. Second Joint EMBS/BMES Conference, Houston, TX, IEEE. 
Ohgoda, O., Sakai, A., Koga, H., Kanai, K., Miyazaki, T. and Niwano, Y. (1998) 
Fibroblast-migration in a wound model of ascorbic acid-supplemented three-
dimensional culture system: the effects of cytokines and malotilate, a new wound 
healing stimulant, on cell-migration. J Dermatol Sci 17(2): 123-31. 
Parenteau, N. (1994) Skin Equivalents. Keratinocyte Methods. Leigh, I. and Watt, F., 
Cambridge University Press: 45-54. 
Parry, D.A. (1988) The molecular and fibrillar structure of collagen and its relationship to 
the mechanical properties of connective tissue. Biophys Chem 29(1-2): 195-209. 
Pouliot, R., Larouche, D., Auger, F.A., Juhasz, J., Xu, W., Li, H. and Germain, L. (2002) 
Reconstructed human skin produced in vitro and grafted on athymic mice. 
Transplantation 73(11): 1751-7. 
Jan-Eric W. Ahlfors 
  51
Ramshaw, J.A., Casagranda, F., White, J.F., Edwards, G.A., Hunt, J.A., Williams, D.F. 
and Werkmeister, J.A. (1999) Effects of mesh modification on the structure of a 
mandrel-grown biosynthetic vascular prosthesis. J Biomed Mater Res 47(3): 309-
15. 
Ramshaw, J.A., Werkmeister, J.A. and Glattauer, V. (1996) Collagen-based biomaterials. 
Biotechnol Genet Eng Rev 13: 335-82. 
Roeder, B.A., Kokini, K., Sturgis, J.E., Robinson, J.P. and Voytik-Harbin, S.L. (2002) 
Tensile mechanical properties of three-dimensional type I collagen extracellular 
matrices with varied microstructure. J Biomech Eng 124(2): 214-22. 
Sannes, P.L., Khosla, J. and Peters, B.P. (1997) Biosynthesis of sulfated extracellular 
matrices by alveolar type II cells increases with time in culture. Am J Physiol 
273(4 Pt 1): L840-7. 
Seliktar, D., Black, R.A., Vito, R.P. and Nerem, R.M. (2000) Dynamic mechanical 
conditioning of collagen-gel blood vessel constructs induces remodeling in vitro. 
Annals of Biomedical Engineering 28(4): 351-362. 
Senoo, H. and Hata, R. (1994) Extracellular matrix regulates and L-ascorbic acid 2-
phosphate further modulates morphology, proliferation, and collagen synthesis of 
perisinusoidal stellate cells. Biochem Biophys Res Commun 200(2): 999-1006. 
Shipley, G.D. and Ham, R.G. (1983) Multiplication of Swiss 3T3 cells in a serum-free 
medium. Exp Cell Res 146(2): 249-60. 
Siddiqui, A.A., Jaffar, T., Khan, N., Azami, R. and Waqar, M.A. (1992) Effect of 
dexamethasone on collagen synthesis in fibroblasts cultured in collagen lattice. 
Biochem Soc Trans 20(2): 207S. 
Jan-Eric W. Ahlfors 
  52
Tuan, T.L., Song, A., Chang, S., Younai, S. and Nimni, M.E. (1996) In vitro fibroplasia: 
matrix contraction, cell growth, and collagen production of fibroblasts cultured in 
fibrin gels. Exp Cell Res 223(1): 127-34. 
Tucker, R.P., Hammarback, J.A., Jenrath, D.A., Mackie, E.J. and Xu, Y. (1993) Tenascin 
expression in the mouse: in situ localization and induction in vitro by bFGF. J 
Cell Sci 104 ( Pt 1): 69-76. 
Vaccariello, M.A., Javaherian, A., Parenteau, N. and Garlick, J.A. (1999) Use of skin 
equivalent technology in a wound healing model. Methods in Molecular 
Medicine, Vol. 18: Tissue Engineering Methods and Protocols. Morgan, J.R. and 
Yarmush, M.L. Totowa, NJ, Humana Press Inc. 18: 391-405. 
Venable, J.H. and Coggesmall, R. (1965) A simplified lead citrate stain for use in 
electron microscopy. J. Cell Biol. 25: 407-408. 
Warshamana, G.S., Martinez, S., Lasky, J.A., Corti, M. and Brody, A.R. (1998) 
Dexamethasone activates expression of the PDGF-alpha receptor and induces 
lung fibroblast proliferation. Am J Physiol 274(4 Pt 1): L499-507. 
Winston, F.K., Macarak, E.J., Gorfien, S.F. and Thibault, L.E. (1989) A system to 
reproduce and quantify the biomechanical environment of the cell. Journal of 
Applied Physiology 67(1): 397-405. 
Xing, B.R., Li, T.Z., Bian, H.N., Qi, S.H., Xie, J.L., Xu, Y.B. and Hu, X.G. (2003) 
[Comparison of the effects of rhEGF with rhbFGF on the acceleration of wound 
healing]. Zhonghua Shao Shang Za Zhi 19(6): 340-3. 
Zhu, Y., Oganesian, A., Keene, D.R. and Sandell, L.J. (1999) Type IIA procollagen 
containing the cysteine-rich amino propeptide is deposited in the extracellular 
Jan-Eric W. Ahlfors 
  53
matrix of prechondrogenic tissue and binds to TGF-beta1 and BMP-2. J Cell Biol 
144(5): 1069-80. 
Zoppi, N., Ghinelli, A., Gardella, R., Barlati, S. and Colombi, M. (1998) Effect of 
dexamethasone on the assembly of the matrix of fibronectin and on its receptors 
organization in Ehlers-Danlos syndrome skin fibroblasts. Cell Biol Int 22(7-8): 
499-508. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jan-Eric W. Ahlfors 
  54
Appendix 1: Cell-Derived Matrix Protocol 
 
 
 
 Thawing Cells (for 1M cells): 
1. Add 16ml of Growth Media into a T75 flask and place into 10% CO2 incubator for 30min. 
2. Add 3ml of Growth Media to a 15ml polypropylene conical tube, and place in water bath 
3. Thaw cryovial w/ cells in 37ºC waterbath + agitate in hand 
4. Slowly add some Growth Media from conical tube to just thawed cells in cyovial 
5. Mix, pipette out, and place cells in conical tube + repeat (rinse cryovial w/ more media) 
6. Place the cells into T75 flask in the incubator 
7. Replace media with 15ml of fresh Growth Media after 24h (see Feeding Cells below) 
 
 
Feeding & Passaging Cells: 
1. Feed cells 2x / week with same amount of Growth Media (replace) until 90% confluent. 
2. When 90% confluent (takes ~1 week), aspirate media + add 1/3 of media amount (5ml into a 
T75 flask; 8ml into a T150 flask) of 0.05% Trypsin-EDTA  
3. Place in incubator until cells have detached (5-15min) + crack lid to vent 
4. Denature Trypsin with same amount of Growth Media and put entire solution into a 50ml 
polypropylene tube 
5. Repeat for all flasks + go back thru and rinse all flasks with 10ml of Growth Media 
6. Do a Cell Count on each tube 
7. Centrifuge tubes at 1,000rpm for 6min 
8. Aspirate supernatant  
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9. Based on Cell count, dilute cells w/ Growth Media to a concentration of ~ 1M / 25ml      
(1M / 25ml in a T150 flask) and seed into flasks 
 
 
Freezing Cells: 
Identical to Steps 2-8 of Feeding & Passaging Cells Protocol, then: 
9. Based on Cell count, dilute cells w/ Cryo Media to a concentration of 1M / ml 
10. Put 1ml of solution / cryovial 
11. Place cryovials in Styrofoam and put into -80ºC freezer for a few days, and then store in 
liquid nitrogen 
 
 
 
Cell-Derived Matrix (CDM): 
Identical to Steps 2-8 of Feeding & Passaging Cells Protocol, then: 
9. Based on Cell count, dilute cells w/ CDM Media to a concentration of: a) for wells: 2M / 5ml; 
b) for TransWells: 2M / 2ml.  
10. a) For wells: put 5ml of CDM Media w/ cells into the wells;  b) For TransWells: Put 3ml of 
CDM Media under wells, and 2ml of CDM Media w/ cells onto the TransWells. 
11. Feed cells every 2 days with same amount of CDM Media:  a)  for wells: 5ml;                           
b)  for TransWells: 2ml above, 3ml below. 
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Growth Media: DMEM + 10% BCS + 1% Pen/Strep/AmphotericinB  (37ºC)   
Cryo Media: DMEM + 10% BCS + 10% DMSO 
CDM Media – 500ml:  
• 3:1 DMEM : Ham’s F12 + 1% Pen/Strep/AmphotericinB  – 360ml : 120ml + 5ml 
• 4 x 10-3M Glutamax (10ml/500ml) - 10ml 
• 8.61 x 10-7M Insulin (0.25ml/500ml) - 250µl 
From -20ºC Freezer: 
• 1.0 x 10-4M Ethanolamine (500X = 3µl/ml).  
• 5.2 x 10-4M L-ascorbic acid phosphate magnesium salt n-hydrate (500X = 75mg/ml). 
• 3.3 x 10-6M Glutathione (reduced) (500X = 500µg/ml) 
• 1.0 x 10-7M Dexamethasone (500X = 19.7µg/ml). 
• 3.9 x 10-8M Selenious Acid (500X = 2.5µg/ml). 
• 2.0 x 10-10M  L-3,3’,5-Triiodothyronine(dissolve in EtOH first) (500X = 67.5ng/ml). 
• 2.8 x 10-10M bFGF (500X = 2.5µg/ml in 1X PBS) - 10µg in 4ml 1X PBS. 
• 4.2 x 10-10M EGF (500X = 1.25µg/ml in 1X PBS with 2.5g/L Serum Albumin) -                      
100µg + 0.2g Human Serum 
Albumin in 80ml 1X PBS. 
 
Cell Count: 
• Pipette 100µl of cell suspension + 100µl of 0.04% trypan blue into an 
Eppendorf tube 
• Pipette out 10µl of mixture and put into hematocytometer 
• Cell count: # of cells / ml = 20,000 x Average # of cells / Quadrant 
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Appendix 2: BIOMECHANICAL ANALYSIS PROTOCOL 
 
 
 
1. Remove media from wells and fill wells with ddH2O. After 5 minutes, remove 
ddH2O and add new ddH2O for 30 minutes. (The ddH2O lyses the cells due to the 
high osmotic pressure built up in the cells due to the low osmolarity of the ddH2O 
relative to the inside of the cells. This eliminates the contractile forces otherwise 
produced by the fibroblasts, and allows the samples to be mechanically tested 
without contracting into themselves. The lysing of the cells releases lysosomes 
into the ddH2O that might negatively affect the matrix. The ddH2O is therefore 
changed after 5 minutes to decrease the concentration of the lysosomes.) 
2. After 30 minutes, remove ddH2O from wells and replace with room temperature 
1X phosphate buffered saline (PBS). (This equilibrates the samples for 
biomechanical testing.)  
3. Measure and record the thickness of each sample with the laser displacement 
system of the mechanical membrane inflation device after being slightly 
compressed by the small reflective disk (1.3g, 1.3cm diameter) for 1 minute. (This 
is to reduce the error due to the hydration state of the samples. The software 
program can be made to display the thickness by setting the 0 value for the small 
reflective disk on the flat stage before placing any samples between the disk and 
the flat stage. Make sure the laser is centered on the reflective disk.)    
4. After all thicknesses have been measured, remove the flat stage and adjust the 
height of the laser so that the faceplate gives a reading of 0 height. Center the 
laser over the 1cm diameter opening in the faceplate. Place one sample at a time 
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over the 1cm diameter opening for mechanical testing. Make sure that the sample 
lies flat and over the O-ring channel. Place O-ring over the sample without 
moving it, and then clamp it down. (During clamping, the entire circumference of 
the sample is forced into the O-ring channel on the faceplate, which will prevent 
“waffling” of the sample in the test region. An even clamping force is created 
around the circumference of the sample by the clamping plate, which is also 
guided and kept from rotating relative to the sample by two pins.) 
5. Start data acquisition on the computer, and inflate the samples with PBS at a 
constant rate of 1 ml/min (thinner samples need a higher rate, while a lower rate 
can be used for thicker samples for greater accuracy). When the sample bursts, 
stop the data acquisition and infusion pump. Record the size and location of the 
burst in the sample before replacing it with the next sample. (The tissue inflation 
device measures the displacement and pressure at which a sample bursts. The 
increasing pressure applied to the sample is measured by an on-board pressure 
transducer (model PX102-025GV, Omega Engineering, Stamford, CT). The 
displacement of the center of the cap is measured with a laser displacement 
system (LDS-080, Keyence, Woodcliff Lake, NJ).) 
6. Measure the Wet Weight of each sample, and then lyophilize overnight and 
measure the Dry Weight. Place in –80°C freezer for later biochemical analysis. 
(The –80°C temperature will help to prevent any collagen degradation.) 
 
The sample is circularly clamped at and inflated through a 1cm diameter opening, thus 
causing the sample to form a spherical cap before failing. 
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• The maximum membrane tension, T, is calculated using the Law of Laplace for a 
spherical membrane: 
T = ½ PR, 
where P is the pressure (conversion factor: (133.3 N/m2)/mmHg) when the tissue 
bursts and R is the corresponding radius at the point of rupture, calculated 
assuming a spherical cap geometry by: 
    R = (w2 + a2) / 2w, 
where a is the radius of the clamp (5mm) and w is the displacement at the center 
of the sample at failure measured by the laser.  
 
• The ultimate tensile strength (UTS) is calculated by: 
  UTS = T / t, 
where t is the thickness of type-matched specimens before inflation. Since the 
thickness measurements are obtained after the samples have been isotonically 
compressed by a 1.3g weight for 1min, the error due to the hydration state of the 
samples is reduced. The actual thickness at the time of bursting is less than this 
value since the samples are inflated. 
 
• The ultimate tensile strength per collagen density (UTS / Collagen Density) is 
calculated by: 
  UTS / Collagen Density = UTS / (Total Collagen / πt(D/2)2) 
        = T / (Total Collagen / π(D/2)2), 
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where D is the diameter of the constructs (2.4cm for TransWells). This value 
gives an accurate measure of strength of the constructs per unit of collagen since it is 
independent of the thickness of the samples.  
 
• The failure strain is determined from the equibiaxial strain at the pole estimated 
from the displacement data using the approximate relationship: 
Failure Strain ≈ 2/3 (w / a)2 – 2/15 (w / a)4 + 2/35 (w / a)6. 
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Appendix 3: BIOCHEMICAL ANALYSIS PROTOCOL 
 
1. Obtain wet weight of samples, lyophilize overnight, and then measure dry weight. 
Place lyophilized samples in –86ºC freezer (to prevent collagen degradation) for 
later biochemical analysis, or go to next step. 
2. Solubilize each lyophilized sample in 1ml pepsin (Sigma # P-6887)(1 mg/ml in 
0.5M acetic acid (EMD Chemicals # AX0073P-5) and incubate overnight at 20°C 
with rotation. Centrifuge samples at 14000 rpm for 1 hour at 15°C, and transfer 
supernatant into separate 2ml Eppendorf tubes. (The pellet contains the remains of 
cells and ECM. The supernatant contains the soluble collagen. Collagen is 
soluble, so it will not go into the pellet. A high salt concentration (4M NaCl for 
samples with neutral pH, and 2M NaCl for samples in acetic acid) would be 
needed to precipitate the collagen out of solution.) Repeat this extraction step to 
achieve complete extraction of the pepsin and acid soluble fraction of collagen.  
3. Combine the supernatants from the first and second extractions, and use 100µl of 
this to determine non-cross-linked collagen content with the Sircol™ Assay 
(Biocolor, Belfast, N. Ireland). To confirm results, a 200 µl aliquot of the soluble 
collagen extract can be used to determine collagen content by hydroxyproline 
assay (NOTE: this value will be higher since it will include collagen that was 
degraded during growth). 
4. Use a 50µl aliquot of the extract to determine total non-collagenous protein 
content with the Tp-Blue™ Total Protein Assay (Biocolor). Generate standard 
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curve by adding 5ml of reagent dye per tube, mixing with 0-500µl of the included 
bovine serum albumin, and reading at 595nm. Add the 50µl aliquot of the extract 
to 5ml of reagent dye, read at 595nm, and use standard curve to determine total 
protein content less collagen. Add this amount to the total collagen amount that 
will be obtained to get total protein amount. 
5. Digest the remaining pellets with Proteinase K (Invitrogen # 25530-049), 50µg in 
500µl solution of 10mM EDTA and 0.1M sodium phosphate (pH 6.5)(0.1M 
sodium phosphate is made by mixing 30ml 1M Na2HPO4 (Fisher # BP332-1), 
70ml 1M NaH2PO4 (Fisher # BP329-1) and 900ml H2O) overnight at 60°C. 
(Proteinase K is a serine protease with broad specifity towards aliphatic, aromatic 
and other hydrophobic amino acids. It digests all proteins into small peptides and 
makes them soluble. After digestion of the proteins, the DNA, proteoglycans and 
glycosaminoglycans are released into the solution.) 
6. Use a 100µl aliquot of the supernatant to determine sulfated glycosaminoglycan 
and proteoglycan content (not including hyaluronic acid) with the Blycan™ 
Assay (Biocolor, Belfast, N. Ireland).  
7. Use a 10µl aliquot of the supernatant to determine DNA content. The number of 
cells per sample can be calculated from the measured amount of DNA using 
Hoechst 33258 dye (Amersham Biosciences # 80-6226-87) and a DyNA Quant 
200 fluorometer (Amersham, designed specifically for the quantification of low 
DNA concentrations using Hoechst 33258 dye, with a fixed excitation bandpass 
source (365 nm) and an emission bandpass filter (460 nm)) based on the known 
DNA content per cell of 8pg. Add 10µl sample to the cuvette with 2ml TNE 
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Buffer (10mM Tris, 200mM NaCI, 1mM EDTA, pH 7.4), mix, place cuvette in 
flurometer and read the concentration. Calibrate DyNA Quant 200 using 10ng 
Calf thymus DNA (add 10ng of standard DNA to the cuvette with 2ml TNE 
Buffer, mix, place cuvette in flurometer and press CALIB).  
8. Use a 200µl aliquot of the supernatant to estimate cross-linked collagen content 
with a hydroxyproline assay: 
a) Hydrolyze each 200µl sample in 200µl of 12M HCl (final HCl 
concentration: 6.0M) in 1.5ml screw cap tubes for 16 hours at 110oC, 
followed by drying of the samples under vacuum. 
b) Reconstitute samples (1-5 µg of hydroxyproline) to 2.0ml with Assay 
Buffer.  
Assay Buffer consists of: 5g/l citric acid (Sigma # C1909), 1.2ml/l glacial 
acetic acid (EMD Chemicals # AX0073P-5), 12g/l sodium acetate (VWR 
# MK776804), and 3.4g/l sodium hydroxide (VWR # MK770810). (Stock 
Buffer contains 50g of citric acid (H2O) (Sigma # C1909), 12ml of glacial 
acetic acid (EMD # AX0073P-5), 120g of sodium acetate (VWR # 
MK776804), 3H2O and 34g of NaOH (VWR # MK770810) in 1.0 liter of 
solution. Stock Buffer solution is diluted tenfold with H2O to make Assay 
Buffer.)  
c) Add 1.0ml of Chloramine-T Reagent and stand for 20 minutes at room 
temperature.  
Chloramine-T Reagent is made from: 1.41g of chloramine-T (VWR # 
VW3506-0) dissolved in 20.7ml of H2O and mixed with 26ml of n-
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propanol (VWR # MK303508) and 53.3ml of Stock Buffer. This reagent 
is stable at 4°C for 2 weeks. 
d) Add 1.0ml of freshly prepared Dimethylaminobenzaldehyde Reagent 
and mix throroughly.  
Dimethylaminobenzaldehyde Reagent: 15g of  p-
dimethylaminobenzaldehyde (Sigma # D-2004) is suspended in 60ml of n-
propanol (VWR # MK303508), and 26ml of 60% perchloric acid (VWR # 
EM-PX0396D-4) is added slowly. (Use a fume hood with protective 
goggles!) 
e) Incubate tubes at 60oC for 15 minutes, followed by cooling in tap water 
for 5 minutes. 
f) Measure the absorbance of each sample at 550nm within 45 minutes. 
Correlate absorbance readings with collagen amount using a standard 
curve and a conversion factor of 10µg collagen to 1µg 4-hydroxyproline. 
Create standard curve with known amounts of Trans-4-hydroxy-L-proline 
(Sigma # 56250) and hydrolyzed rat tail Collagen, Type 1 (Biocolor, 
Belfast, N. Ireland). 
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Appendix 4: Steps in Development of Chemically Defined Medium 
 
 
A serum-free base medium was first developed based on a number of serum-free 
media from literature (Bettger et al., 1981; Shipley and Ham, 1983; Parenteau, 1994; 
Vaccariello et al., 1999) (see chart on next page). The effects on the tension, thickness, 
ultimate tensile strength (UTS) and failure strain of a number of components after 3 
weeks in culture was determined in series. Apart from the last two sets of experiments, all 
samples were grown on the bottom of regular 6 well plates, unless otherwise indicated. 
Growth factors were added into the base medium at the beginning of each 3-week study. 
When a particular component was found to significantly increase the strength and 
thickness of the CDMs at a particular concentration, it continued to be added into the 
media at that concentration throughout the study. The chemically defined media 
formulation that was developed from all these studies is shown below (Ahlfors, 2003). 
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The first component that was tested was L-ascorbic acid phosphate magnesium 
salt n-hydrate (Wako Pure Chemicals, Japan). L-ascorbate at 50 µg/ml (289µM) has 
been found to significantly increase fibroblast growth and ECM synthesis by 
upregulating the expression of proalpha(1)(I) and proalpha(2)(I) collagen (Grinnell et al., 
1989; Hata and Senoo, 1989; Huang et al., 1993; Kurata et al., 1993; Girton et al., 2000; 
Hoerstrup et al., 2000; Laplante et al., 2001; Pouliot et al., 2002). However, since L-
ascorbate breaks down within 24h in culture, a more stable form of L-ascorbate, L-
ascorbic acid 2-phosphate has been adopted in several studies (Hata and Senoo, 1989; 
Geesin et al., 1993; Kurata et al., 1993; Senoo and Hata, 1994; Ohgoda et al., 1998; 
Hoerstrup et al., 1999). A more stable form is L-ascorbic acid phosphate magnesium salt 
n-hydrate, which has a more than one week stability in culture and has been found to be 
most effective for the production of ECM at a 1mM concentration for fibroblast cultures 
(Ishikawa et al., 1997).  
 The three concentrations of L-ascorbic acid phosphate magnesium salt n-hydrate 
tested were: 50 µg/ml (173µM), 150 µg/ml (519µM), and 300 µg/ml (1,038µM). After 4 
weeks in culture, the wet weights (and dry weights) of these groups were: 
 
 Sample 1 (mg) Sample 2 (mg) Sample 3 (mg) Sample 4 (mg) Average (mg) 
50 µg/ml 31.7 (1.3) 30.7 (1.2) 32.1 (1.3) 31.3 (1.3) 31.5 (1.3) 
150 µg/ml 32.6 (1.6) 31.8 (1.5) 32.8 (1.7) 32.4 (1.6) 32.4 (1.6) 
300 µg/ml 30.3 (1.5) 29.8 (1.6) 30.7 (1.4) 30.4 (1.5) 30.3 (1.5) 
 
 
According to the above results, 150 µg/ml (519µM) of L-ascorbic acid phosphate 
magnesium salt n-hydrate appeared to cause the cell-derived matrix to produce the most 
extensive ECM. The relatively high wet weight to dry weight ratio of for the 50 µg/ml 
(173µM) concentration indicated that these samples were more hydrated, while the other 
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two groups had more dense ECM presumably due to a greater fraction of the ECM being 
composed of collagen. Mechanical testing on these samples was not performed because 
the samples started curling up at around 2 weeks (experiment was repeated again, with 
the same results of curling) in culture due to polyethylene terephthalate treated cell 
culture wells (BD Biosciences) that were later determined not to be a good attachment 
surface for CDMs. From here onwards, 150 µg/ml (519µM) of L-ascorbic acid phosphate 
magnesium salt n-hydrate was used in the medium.  
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The next two components that were tested were Galactose and Epidermal Growth 
Factor (EGF). For cultures grown over long periods of time, fructose or galactose has 
been used instead of glucose since fructose and galactose reduce the production of acidic 
metabolites since they do not break down to lactic acid and thus permit higher density 
cell cultures (Leibovitz, 1963; Huang et al., 1993). High glucose (4.5 mg/ml) DMEM 
was compared to low glucose (1 mg/ml) DMEM supplemented with 3.5 mg/ml galactose 
(galactose has same molarity as glucose) or 5.75 mg/ml galactose (due to high activity, 
cultures were expected to require more sugars). EGF, on the other hand, stimulates the 
growth and production of non-collagenous proteins, but also inhibits the transcription of 
type 1 collagen genes and thus a lower EGF concentration should increase the strength of 
the ECM (Kurata and Hata, 1991). A previous study had already indicated that 0.5 µg/ml 
of EGF resulted in the strongest cell-derived matrices, but they were so thin that they 
were difficult to handle and test. Ten times this amount, or 5 µg/ml of EGF, resulted in a 
weaker but much thicker cell-derived matrix, and had the best combination of strength 
and thickness of the all the groups. Double of this amount, or 10 µg/ml of EGF, resulted 
in slightly thicker but much weaker samples. The following experiment tested the effects 
of five times the 0.5 µg/ml EGF amount, or 2.5 µg/ml of EGF, versus the 5 µg/ml of EGF 
that had the best combination of strength and thickness in the previous experiment. 
Samples with 0.5 µg/ml EGF and 1.0 µg/ml EGF were also grown in parallel with the 
above samples, but they were sill too thin after 3 weeks to be mechanically testable. 
 The results below indicate that galactose did not improve the thickness and 
significantly reduced the UTS of cell-derived matrices, and thus was not kept in the 
media formulations. The reduced UTS appears to be due to the high glucose in the other 
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samples inducing collagen cross-linking through the process of glycation. The 2.5 µg/ml 
EGF concentration was thinner than the 5 µg/ml concentration, but much stronger. Since 
both the tension and failure strain were also higher for the 2.5 µg/ml EGF samples, it was 
determined that this concentration caused the best combination of properties, and was 
used in the medium from this point onwards. 
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Sample Thickness (mm) Displacement (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain
1a 0.085 2.40 37.5 523.7 0.15
1b 0.065 3.49 21.3 296.9 0.30
1c 0.065 3.19 25.3 352.4 0.25
4a 0.115 2.62 22.7 219.8 0.17
4b 0.100 1.76 31.9 308.7 0.08
4c 0.095 2.07 19.4 187.7 0.11
5a 0.095 4.46 15.1 150.7 0.47
5b 0.105 3.56 8.0 79.9 0.31
5c 0.100 2.84 19.7 196.6 0.20
6a 0.095 2.80 12.5 128.9 0.20
6b 0.085 2.81 7.3 75.9 0.20
6c 0.110 3.47 25.9 268.4 0.30
Thickness (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain
2.5µg/ml EGF (Glucose) 0.072 28.0 391.0 0.23
5µg/ml EGF (Glucose) 0.103 24.7 238.7 0.12
5µg/ml EGF (Galactose) 0.100 14.2 142.4 0.33
5µg/ml EGF (1.5x Galactose) 0.097 15.2 157.7 0.23
Standard 0.012 8.5 118.2 0.08
Deviations 0.010 8.8 85.6 0.05
0.005 5.9 58.8 0.14
0.013 9.6 99.5 0.06
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The fourth component that was tested was Dexamethasone. Dexamethasone at 
1nM –100nM concentrations has been shown to significantly increase fibroblast cell 
proliferation in serum-free media (Bettger et al., 1981; Shipley and Ham, 1983) by 
upregulating the PDGF-alpha receptor mRNA and protein (Warshamana et al., 1998), 
which has been shown to significantly extend the dendritic network of fibroblasts in 3D 
matrices (Grinnell, 2003). Dexamethasone has also been shown to be involved in 
increasing ECM growth and strength in FPCLs (Siddiqui et al., 1992; Ramshaw et al., 
1999). This appears to be due to the ability of dexamethasone to promote actin stress 
fiber formation and increased fibronectin matrix accumulation that aid in the more 
effective organization of the ECM (Zoppi et al., 1998; Brenner et al., 2000). Also, the 
increase in collagenase and stromelysin mRNA by EGF that degrade collagen is inhibited 
with the addition of dexamethasone (Delany and Brinckerhoff, 1992). However, 
dexamethasone also starts to downregulate the expression of proalpha(1)(I) collagen at 
around 100nM and higher concentrations, suggesting that the strength of the ECM 
produced by fibroblasts will start decreasing at higher than 100nM dexamethasone 
concentrations (Zoppi et al., 1998). The dexamethasone concentration should thus be 
kept at or below 100nM to retain the ECM growth and strengthening effects of 
dexamethasone. Also, since dexamethasone is a glucocorticoid as is hydrocortisone, 
hydrocortisone was removed from the medium in order to keep it simple.  
The 3 concentrations of Dexamethasone that were tested were 1nM, 10nM, and 
100nM. The 100nM concentration significantly increased the tension, thickness, and UTS 
of cell-derived matrices, and was thus added into the medium from this point onwards. 
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Interestingly, the 1nM concentration of Dexamethasone increased the thickness but not 
the tension of the samples, thus causing a decrease in the UTS of cell derived matrices. 
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Sample Thickness (mm) Displacement (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Dry Weight (mg)
J1 0.100 3.516 34.5 358.9 0.30 4.5
J2 0.110 2.739 33.4 347.1 0.19 4.7
J3 0.085 3.18 22.0 229.0 0.25 5.5
J4 0.090 6.372 24.5 254.6 0.98 5.2
K2 0.120 4.176 55.9 466.1 0.42 5
K3 0.115 4.176 59.7 497.5 0.42 5.6
K4 0.125 4.146 63.2 526.5 0.41 5.8
L1 0.120 2.769 69.3 577.6 0.19 4.8
L3 0.130 3.897 67.7 564.2 0.37 5
L4 0.125 4.104 67.6 563.3 0.41 5.2
Dexamethasone Thickness (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Dry Weight (mg)
1 nM 0.096 28.6 297.4 0.43 5.0
10 nM 0.120 59.6 496.7 0.42 5.5
100 nM 0.125 68.2 568.4 0.32 5.0
Standard 0.011 6.3 65.2 0.37 0.5
Deviations 0.005 3.6 30.2 0.00 0.4
0.005 1.0 8.0 0.11 0.2
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The next set of components that were tested were the amino acids L-Proline and 
Glycine. The addition of L-Proline and Glycine would be expected to increase the 
synthesis of collagen in CDMs since L-Proline and Glycine are the major components of 
collagen (in a 100:68 ratio of Gly:Pro) that is the major structural protein that provides 
strength to extracellular matrices (Ramshaw et al., 1996). In fact, Organogenesis, Inc. has 
been adding Glycine and L-proline (in an approximate 1:1 ratio) to their media that they 
use to produce Apligraf™ and other products containing fibroblasts (Murphy and 
Ronfard, 2002).  
The effects of 3 different concentrations of L-proline (and the corresponding 
concentration of Glycine to maintain a 100:68 ratio of Gly:Pro) were tested over a 3 week 
period: 0.3mM, 1mM, and 3mM. Unfortunately, all the 1mM samples (6 samples in all) 
curled up into little balls after approximately 1 week in culture. Although the 3mM 
samples had a slightly higher UTS, they had a significantly smaller tension, thickness, 
and failure strain than the 0.3mM samples. However, the 0.3mM samples had a much 
reduced UTS from the previous set of experiments (568.4 ± 8.0 kPa versus 422.1 ± 53.4 
kPa), indicating that the addition of L-proline and Glycine caused the UTS of cell-derived 
matrices to decrease significantly. This observation indicated that the 1mM concentration 
most likely as well caused a decrease in the UTS from the previous set of experiments, 
even though the contraction of all the samples into balls indicated the possibility of a high 
presence of collagen. Thus, L-proline and Glycine were not added into the media.  
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Sample Thickness (mm) Displacement (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Dry Weight (mg)
G1 0.135 2.77 50.9 412.6 0.19 4.4
G2 0.140 3.58 56.8 460.6 0.31 5
G3 0.130 3.38 62.6 507.5 0.28 4.8
G4 0.115 2.75 50.3 407.6 0.19 4.4
G5 0.110 2.55 47.1 382.0 0.17 4.2
G6 0.110 2.90 44.7 362.2 0.21 4.7
H1 - H6
I1 0.080 2.84 39.3 501.8 0.20 3.8
I3 0.075 2.74 33.4 426.5 0.19 4
I4 0.080 2.60 39.8 507.5 0.17 4
L-Proline Thickness (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Dry Weight (mg)
0.3 mM 0.123 52.1 422.1 0.23 4.6
3 mM 0.078 37.5 478.6 0.19 3.9
Standard 0.013 6.6 53.4 0.06 0.3
Deviations 0.003 3.5 45.2 0.02 0.1
100:60 Glycine:L-Proline
All 1 mM samples contracted in the first week 
 
Thickness (mm)
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.3 mM 3 mM
Ultimate Tensile Strength (kPa)
0.0
100.0
200.0
300.0
400.0
500.0
600.0
0.3 mM 3 mM
Failure Strain
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.3 mM 3 mM
Tension (N/m)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
0.3 mM 3 mM
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The seventh component that was tested was the amino acid L-cysteine. L-cysteine 
would be expected to increase the mechanical strength of CDMs since it is known to 
increase ECM cross-linking through disulfide bridges and is involved in modulating the 
synthetic phenotype of fibroblasts (Sannes et al., 1997; Basu et al., 1999; Zhu et al., 
1999; Carlson et al., 2003). It is also found in high concentrations in the protein SPARC 
that increases the tensile strength of collagen fibers by directing formation and 
maintaining the stability of these fibers (Bradshaw et al., 2003). 
The effects of the 3 different concentrations of L-cysteine that were tested were: 
0.1mM, 0.3mM, and 3mM. These 3 groups were grown in parallel on 12-well plates (1M 
cells / well) for 3 weeks. Unfortunately, all the 1.0mM samples got infected with fungus. 
However, the results for the 0.3mM and 3mM samples indicate that the tension, 
thickness, and UTS might be fairly constant throughout the range of concentrations. 
Although these values were higher than in previous experiments, these increases 
appeared to be due to the higher density of cells used on the 12-well plate (1M/3.8cm2 vs. 
2M/9.6cm2), and thus the addition of L-cysteine did not appear to have any significant 
effect on these values on cell-derived matrices, and thus was not added to the medium 
being developed. However, the failure strain approximately doubles with the addition of 
0.3mM of L-cysteine. Thus, the addition of L-cysteine could come in handy when the 
failure strain of cell-derived matrices would need to be significantly increased. 
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Thickness (mm)
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.3 mM 3 M
Ultimate Tensile Strength (kPa)
0.0
100.0
200.0
300.0
400.0
500.0
600.0
700.0
800.0
900.0
0.3 mM 3 M
Failure Strain
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
0.3 mM 3 M
Tension (N/m)
0.0
20.0
40.0
60.0
80.0
100.0
120.0
0.3 mM 3 M
 
 
Sample Thickness (mm) Displacement (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Dry Weight (mg)
M1 0.145 6.50 99.6 730.8 1.02 4.3
M2 0.130 8.06 104.0 763.1 1.83 5.6
M3 0.135 5.41 67.6 496.5 0.69 4.2
M4 0.135 5.39 81.4 597.2 0.68 5.4
N1 - N4
O1 0.140 5.00 - - 0.59 5.3
O2 0.145 5.44 82.2 587.0 0.70 4.6
O3 0.135 4.37 80.1 572.0 0.46 4.8
L-Cysteine Thickness (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Dry Weight (mg)
0.3 mM 0.136 88.1 646.9 1.06 4.9
3 M 0.140 81.1 579.5 0.58 4.9
Standard 0.006 16.8 123.3 0.54 0.7
Deviations 0.005 1.5 10.7 0.12 0.4
All 1 mM samples got infected during last week of culture
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The eighth component that was tested was basic fibroblast growth factor. Basic 
fibroblast growth factor (bFGF) at 5-25ng/ml concentrations has been show to stimulate 
collagen production by fibroblasts in monolayers, and thus increasing the strength of the 
ECM produced by these fibroblasts (Shipley and Ham, 1983; Gospodarowicz et al., 
1987; Butt et al., 1995). bFGF is thought to play an important role in normal tissue repair 
and wound healing, and is a potent mitogenic and chemotactic factor for fibroblasts, 
regulating proliferation and extracellular matrix (ECM) production by these cells 
(Milewski et al., 1998; Aktas and Kayton, 2000). It has also been shown to mediate 
fibroblast migration (Kondo et al., 1993). It is also a potent inducer of tenascin 
expression, which is involved in cell motility, cell proliferation, and tissue modeling 
(Tucker et al., 1993). Also, since the mechanisms underlying the effects of epidermal 
growth factor (EGF) overlap with those of bFGF, the addition of bFGF allows a lower 
concentration of EGF to be used without diminishing any of the EGF’s effects on ECM 
development (Abe et al., 1990). 
The effect of 5 µg/ml of bFGF on the growth of cell-derived matrices was 
investigated over a 3-week time period. This is a standard amount used in media 
containing bFGF. Higher concentrations generally have more beneficial effects, but 
bFGF is very expensive. The addition of 5 µg/ml of bFGF significantly increased the 
tension and UTS of cell-derived matrices, but not the thickness. Basic fibroblast growth 
factor was thus included in the medium from this point onwards.  
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Thickness (mm)
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0.160
0.180
No bFGF 5 µg/ml bFGF
Ultimate Tensile Strength (kPa)
0.0
100.0
200.0
300.0
400.0
500.0
600.0
700.0
800.0
No bFGF 5 µg/ml bFGF
Failure Strain
0.00
0.10
0.20
0.30
0.40
0.50
0.60
No bFGF 5 µg/ml bFGF
Tension (N/m)
0.0
20.0
40.0
60.0
80.0
100.0
120.0
No bFGF 5 µg/ml bFGF
 
 
 
Sample Thickness (mm) Displacement (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain
A 0.145 3.2 73.0 534.2 0.25
B 0.135 3.2 68.3 499.4 0.25
C 0.130 4.8 66.3 485.4 0.55
D 0.150 2.9 103.6 690.5 0.21
E 0.140 3.2 96.0 639.9 0.25
F 0.160 3.3 93.7 624.4 0.27
Thickness (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain
No bFGF 0.137 69.2 506.4 0.35
 µg/ml bFG 0.150 97.7 651.6 0.25
Standard 0.008 3.4 25.2 0.17
Deviations 0.010 5.2 34.6 0.03
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The table below summarizes all the modification that were made to the medium 
and in what order. L-Cysteine (*) was grown in 12-well plates at a 20% higher density 
which resulted in higher values. The resulting medium was later simplified further by 
getting rid of the transferrin and O-Phosphorylethanolamine, since there was no solid 
literature to support the need of these components for the growth of cell-derived matrices. 
The concentration of L-3,3’,5-Triiodothyronine was also increased by ten times to 
support the necessary increased rate of cell metabolism of the fibroblasts within cell-
derived matrices. 
 
Component Base Media L-Ascorbate Galactose EGF Dexamethasone 100:68 Glycine:L-Proline L-Cysteine* bFGF Ahlfors, 2003
Base Media 3:1 DMEM:F12 3:1 DMEM:F12 3:1 DMEM:F12 3:1 DMEM:F12 3:1 DMEM:F12 3:1 DMEM:F12 3:1 DMEM:F12 3:1 DMEM:F12 3:1 DMEM:F12
Fetal Bovine Serum
Glucose 4.5 mg/ml (25mM) 4.5 mg/ml (25mM) 1.0mg/ml + 3.5mg/ml Galactose 4.5 mg/ml (25mM) 4.5 mg/ml (25mM) 4.5 mg/ml (25mM) 4.5 mg/ml (25mM) 4.5 mg/ml (25mM) 4.5 mg/ml (25mM)
L-Glutamine 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax 3.25mM + 4mM Glutamax
Hepes
Liposome B
Albumin
Epidermal Growth Factor 10 ng/ml (1.67nM) 10 ng/ml (1.67nM) 5 ng/ml (0.83nM) 2.5 ng/ml (0.42nM) 2.5 ng/ml (0.42nM) 2.5 ng/ml (0.42nM) 2.5 ng/ml (0.42nM) 2.5 ng/ml (0.42nM) 2.5 ng/ml (0.42nM)
Basic Fibroblast Growth Factor 5 ng/ml (0.28nM) 5 ng/ml (0.28nM)
Platelet Derived Growth Factor
Progesterone
Insulin 5 µg/ml (86.1µM) 5 µg/ml (86.1µM) 5 µg/ml (86.1µM) 5 µg/ml (86.1µM) 5 µg/ml (86.1µM) 5 µg/ml (86.1µM) 5 µg/ml (86.1µM) 5 µg/ml (86.1µM) 5 µg/ml (86.1µM)
Dexamethasone 39.3 ng/ml (100nM) 39.3 ng/ml (100nM) 39.3 ng/ml (100nM) 39.3 ng/ml (100nM) 39.3 ng/ml (100nM)
Hydrocortisone 400 ng/ml (1.1µM) 400 ng/ml (1.1µM) 400 ng/ml (1.1µM) 400 ng/ml (1.1µM) -
L-3,3’,5-Triiodothyronine 13.5 pg/ml (20pM) 13.5 pg/ml (20pM) 13.5 pg/ml (20pM) 13.5 pg/ml (20pM) 13.5 pg/ml (20pM) 13.5 pg/ml (20pM) 13.5 pg/ml (20pM) 13.5 pg/ml (20pM) 135 pg/ml (200pM)
Transferrin 5 µg/ml (62.5nM) 5 µg/ml (62.5nM) 5 µg/ml (62.5nM) 5 µg/ml (62.5nM) 5 µg/ml (62.5nM) 5 µg/ml (62.5nM) 5 µg/ml (62.5nM) 5 µg/ml (62.5nM) -
Ethanolamine 6.1 µg/ml (100µM) 6.1 µg/ml (100µM) 6.1 µg/ml (100µM) 6.1 µg/ml (100µM) 6.1 µg/ml (100µM) 6.1 µg/ml (100µM) 6.1 µg/ml (100µM) 6.1 µg/ml (100µM) 6.1 µg/ml (100µM)
O-Phosphorylethanolamine  14.1 µg/ml (100µM) 14.1 µg/ml (100µM) 14.1 µg/ml (100µM) 14.1 µg/ml (100µM) 14.1 µg/ml (100µM) 14.1 µg/ml (100µM) 14.1 µg/ml (100µM) 14.1 µg/ml (100µM) -
Selenious Acid 5 ng/ml (39nM) 5 ng/ml (39nM) 5 ng/ml (39nM) 5 ng/ml (39nM) 5 ng/ml (39nM) 5 ng/ml (39nM) 5 ng/ml (39nM) 5 ng/ml (39nM) 5 ng/ml (39nM)
Ascorbic Acid 50 µg/ml (173µM) 150 µg/ml (519µM) 150 µg/ml (519µM) 150 µg/ml (519µM) 150 µg/ml (519µM) 150 µg/ml (519µM) 150 µg/ml (519µM) 150 µg/ml (519µM) 150 µg/ml (519µM)
L-Proline 25.9 µg/ml (225µM)
Glycine 8.7 µg/ml (116µM)
L-Cysteine 30.5 µg/ml (250µM)
Copper Sulfate
Sodium Sulfate
Dithiothreitol
Phosphoenolpyruvate
Prostaglandin E1
Prostaglandin F2 α
Glutathione (reduced) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM) 1 µg/ml (3.25µM)
Adenine
Strontium Chloride
Ammonium Metavanadate
Manganous Chloride
Cholera Toxin
TENSION     (23.1% increase 24.7 ± 8.8 N/m 14.2 ± 5.9 N/m 28.0 ± 8.5 N/m 68.2 ± 1.0 N/m 52.1 ± 6.6 N/m 88.1 ± 16.8 N/m 97.7 ± 5.2 N/m 156.9 ± 8.1 N/m
THICKNESS in Dry Weight) → 103 ± 10 µm 100 ± 5 µm 72 ± 12 µm 125 ± 5 µm 123 ± 13 µm 136 ± 6 µm 150 ± 10 µm 225 ± 7 µm
UTS 238.7 ± 85.6 kPa 142.4 ± 58.8 kPa 391.0 ± 118.2 kPa 568.4 ± 8.0 kPa 422.1 ± 53.4 kPa 646.9 ± 123.3 kPa 651.6 ± 34.6 kPa 697.1 ± 36.1 kPa
FAILURE STRAIN 0.12 ± 0.05 0.33 ± 0.14 0.23 ± 0.06 0.32 ± 0.11 0.23 ± 0.06 1.06 ± 0.54 0.25 ± 0.03 0.31 ± 0.06
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The results for cell-derived matrices seeded with 2.5million HFFs (for faster 
growth) on TransWells™ and fed with the resulting medium for 3 weeks are shown 
below (as ^CDM). These are compared to CDMs and collagen gels that were grown in 
parallel to the ^CDMs and fed with the serum-supplemented medium. The results below 
show higher thickness but lower UTS values than for the previous experiment with bFGF 
(where the media was identical), indicating that TransWells promote the growth of thick 
CDMs but do not appear to increase the UTS. Starting cell number did not appear to have 
a significant effect (as long as cells are seeded at “superconfluent” densities) on the 
growth and strengthening of the chemically-defined medium fed samples. However, the 
higher starting cell number appear to cause a significant increase in the UTS of the 
serum-supplemented samples (both CDMs and collagen gels) – compare to CDMs and 
collagen gels in the reported (next) experiments where starting cell number was 2M. 
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Thickness (mm)
0.000
0.050
0.100
0.150
0.200
0.250
CDM CG ^CDM
Ultimate Tensile Strength (kPa)
0.0
100.0
200.0
300.0
400.0
500.0
600.0
700.0
CDM CG ^CDM
Failure Strain
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
CDM CG ^CDM
Tension (N/m)
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
CDM CG ^CDM
Cell Number (Million)
0.0
2.0
4.0
6.0
CDM CG ^CDM
Total Protein (mg)
0.00
0.50
1.00
1.50
2.00
2.50
3.00
CDM CG ^CDM
Total Collagen (mg)
0.00
0.50
1.00
1.50
2.00
CDM CG ^CDM
% Collagen
0.0
20.0
40.0
60.0
80.0
100.0
CDM CG ^CDM
Insoluble Collagen Fraction (%)
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
CDM CG ^CDM
Total Proteoglycans and Glycosaminoglycans (µg)
0.0
10.0
20.0
30.0
40.0
50.0
CDM CG ^CDM
% Proteoglycans and Glycosaminoglycans
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
CDM CG ^CDM
UTS / Collagen Density (kPa/mg/cm3)
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
CDM CG ^CDM
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Sample Thickness (mm) Displacement (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Wet Weight (mg) Dry Weight (mg)
[D1] 0.110 3.91 38.5 320.8 0.37 24.7 1.8
[D2] 0.120 2.78 42.3 352.5 0.20 23.6 1.9
[D3] 0.130 3.22 47.7 397.5 0.26 24.5 1.9
[C1] 0.100 3.29 11.9 109.8 0.27 29.7 1.8
[C2] 0.110 2.55 27.8 256.6 0.17 28.4 1.7
[C3] 0.120 2.83 29.3 270.5 0.20 28.8 1.6
[C4] 0.100 2.33 26.7 246.5 0.14 29.6 1.6
[C5] 0.110 3.08 27.4 252.9 0.24 31.6 1.7
[C6] 0.110 2.20 23.2 214.2 0.12 30.4 1.7
[A1] 0.190 3.63 104.8 532.9 0.32 87.0 3.0
[A2] 0.200 3.50 110.5 561.9 0.30 92.4 3.1
[A3] 0.200 3.43 119.2 606.1 0.29 88.1 3.2
Thickness (mm) Tension (N/m) Ultimate Tensile Strength (kPa) Failure Strain Wet Weight (mg) Dry Weight (mg)
10% FBS CDM CDM 0.120 42.8 356.9 0.27 24.3 1.9
10% FBS FPCL CG 0.108 24.4 225.1 0.19 29.8 1.7
Ahlfors CDM ^CDM 0.197 111.5 566.9 0.30 89.2 3.1
Standard 0.010 4.6 38.5 0.09 0.6 0.06
Deviations 0.008 6.4 59.5 0.06 1.1 0.08
0.006 7.3 36.9 0.02 2.9 0.10
………………………………………………………………………………………………………….. 
Wet Weight / Dry Weight Total Protein (mg) Total Collagen (mg) % Collagen Collagen Density (mg/cm3) UTS / Collagen Density (kPa/mg/cm3)
13.7 1.4 0.92 68.1 18.5 17.4
12.4 1.4 0.91 63.9 16.8 21.0
12.9 1.4 0.96 67.4 16.3 24.4
16.5 1.4 1.02 75.6 22.5 4.9
16.7 1.3 1.04 81.2 20.8 12.3
18.0 1.2 0.98 81.7 18.1 15.0
18.5 1.2 1.03 85.4 22.7 10.9
18.6 1.3 1.03 80.8 20.7 12.2
17.9 1.3 0.99 77.6 19.9 10.8
29.0 2.3 1.54 68.4 17.9 29.7
29.8 2.3 1.60 68.8 17.7 31.8
27.5 2.4 1.56 65.0 17.2 35.2
Wet Weight / Dry Weight Total Protein (mg) Total Collagen (mg) % Collagen Collagen Density (mg/cm3) UTS / Collagen Density (kPa/mg/cm3)
13.0 1.40 0.93 66.5 17.2 20.9
17.7 1.26 1.01 80.4 20.8 11.0
28.8 2.33 1.57 67.4 17.6 32.2
0.7 0.04 0.03 2.3 1.1 3.5
0.9 0.06 0.02 3.4 1.7 3.4
1.2 0.08 0.03 2.1 0.3 2.7
………………………………………………………………………………………………………….. 
Insoluble Collagen Fraction (mg) Insoluble Collagen Fraction (%) Total Proteoglycans and Glycosaminoglycans (µg) % Proteoglycans and Glycosaminoglycans Cell Number (Million)
0.026 2.8 30.4 2.3 3.5
0.026 2.9 29.8 2.1 3.6
0.027 2.8 30.7 2.2 3.7
0.017 1.7 39.2 2.9 3.7
0.016 1.5 40.5 3.2 3.8
0.014 1.4 39.3 3.3 3.6
0.018 1.8 38.8 3.2 3.7
0.015 1.5 40.1 3.1 3.9
0.015 1.5 42.0 3.3 3.6
0.199 12.9 35.5 1.6 4.1
0.200 12.5 37.0 1.6 4.0
0.199 12.8 36.0 1.5 3.9
Insoluble Collagen Fraction (mg) Insoluble Collagen Fraction (%) Total Proteoglycans and Glycosaminoglycans (µg) % Proteoglycans and Glycosaminoglycans Cell Number (Million)
0.026 2.8 30.3 2.2 3.6
0.016 1.6 40.0 3.2 3.7
0.199 12.7 36.2 1.6 4.0
0.001 0.0 0.5 0.1 0.1
0.001 0.1 1.2 0.1 0.1
0.001 0.2 0.8 0.0 0.1
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The resulting medium was simplified further by getting rid of the transferrin and 
O-Phosphorylethanolamine, since there was no solid literature to support the need of 
these components for the growth of cell-derived matrices. The concentration of L-3,3’,5-
Triiodothyronine was also increased by ten times to support the necessary increased rate 
of cell metabolism of the fibroblasts within cell-derived matrices. The results for cell-
derived matrices (*CDMs, **CDM, and BTCs) seeded with 2.0 million HFFs (0.5 
million less than above) on TransWells™ and fed with this medium for 3 weeks are 
shown below. This chemically defined medium increased the thickness and UTS. The 
decreased cell number resulted in a significant decrease in the tension, thickness, total 
protein, and UTS of CDMs and collagen gels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Jan-Eric W. Ahlfors 
  86
Thickness (mm)
0.000
0.100
0.200
0.300
0.400
0.500
CG FG CDM *CDM **CDM
Ultimate Tensile Strength (kPa)
0.0
100.0
200.0
300.0
400.0
500.0
600.0
700.0
800.0
CG FG CDM *CDM **CDM
Failure Strain
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
CG FG CDM *CDM **CDM
Tension (N/m)
0.0
50.0
100.0
150.0
200.0
CG FG CDM *CDM **CDM
Cell Number (Million)
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
CG FG CDM *CDM **CDM
Total Protein (mg)
0.00
1.00
2.00
3.00
4.00
5.00
CG FG CDM *CDM **CDM
Total Collagen (mg)
0.00
0.50
1.00
1.50
2.00
CG FG CDM *CDM **CDM
% Collagen
0.0
20.0
40.0
60.0
80.0
100.0
CG FG CDM *CDM **CDM
Insoluble Collagen Fraction (%)
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
CG FG CDM *CDM **CDM
Total Proteoglycans and Glycosaminoglycans (µg)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
CG FG CDM *CDM **CDM
% Proteoglycans and Glycosaminoglycans
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
CG FG CDM *CDM **CDM
UTS / Collagen Density (kPa/mg/cm3)
0.0
10.0
20.0
30.0
40.0
50.0
CG FG CDM *CDM **CDM
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Sample Thickness (mm) Displacement (mm) Spherical Cap Area (mm2) Estimated Burst Thickness (mm) Tension (N/m)
[CDM1] 0.130
[CDM2] 0.120 2.81 103.3 0.091 26.6
[CDM2] 0.130 2.30 95.2 0.107 28.6
[CDM4] 0.120 2.75 102.3 0.092 28.5
[CG1] 0.080 2.30 95.2 0.066 10.3
[CG2] 0.080 2.45 97.4 0.065 17.1
[CG3] 0.090 2.05 91.7 0.077 16.8
[CG4] 0.080 2.12 92.7 0.068 11.4
[FG1] 0.210 3.17 110.1 0.150 25.7
[FG2] 0.220 2.69 101.3 0.171 30.8
[FG3] 0.220 2.89 104.8 0.165 30.4
[FG4] 0.220 2.74 102.1 0.169 29.0
[*CDM1] 0.400 3.88 125.8 0.250 121.3
[*CDM2] 0.390 3.59 119.0 0.257 124.4
[*CDM3] 0.390
[*CDM4] 0.400 3.61 119.5 0.263 127.0
[**CDM1] 0.220 3.27 112.1 0.154 151.1
[**CDM2] 0.230 3.82 124.4 0.145 162.6
Thickness (mm) Displacement (mm) Spherical Cap Area (mm2) Estimated Burst Thickness (mm) Tension (N/m)
10% FBS FPCL CG 0.083 2.23 94.2 0.069 13.9
10% FBS FPFL FG 0.218 2.87 104.6 0.164 29.0
10% FBS CDM CDM 0.125 2.62 100.3 0.097 27.9
Ahlfors CDM *CDM 0.395 3.69 121.4 0.257 124.2
Ahlfors+ CDM **CDM 0.225 3.55 118.3 0.150 156.9
Standard CG 0.005 0.18 2.6 0.006 3.6
Deviations FG 0.005 0.22 4.0 0.010 2.3
CDM 0.006 0.28 4.5 0.009 1.1
*CDM 0.006 0.16 3.8 0.007 2.9
**CDM 0.007 0.39 8.7 0.006 8.1
………………………………………………………………………………………………................... 
Ultimate Tensile Strength (kPa) Estimated True UTS (kPa) Failure Strain Wet Weight (mg) Dry Weight (mg) Wet Weight / Dry Weight Total Protein (mg)
23.8 1.8 13.2 1.2
212.8 274.6 0.20 24.1 1.9 12.7 1.3
228.8 295.2 0.14 23.9 1.9 12.6 1.3
228.0 294.2 0.19 24.4 1.8 13.6 1.2
124.8 149.6 0.14 23.1 1.4 16.5 1.1
207.3 248.4 0.15 24.5 1.5 16.3 1.1
203.6 244.0 0.11 23.6 1.5 15.7 1.1
138.2 165.6 0.12 23.9 1.4 17.1 1.1
118.2 157.1 0.25 44.3 2.2 20.1 1.5
141.6 188.2 0.18 46.1 2.3 20.0 1.6
139.8 185.8 0.21 45.3 2.2 20.6 1.5
133.3 177.2 0.19 44.9 2.3 19.5 1.6
307.1 472.6 0.37 122.3 6.3 19.4 4.4
314.9 484.7 0.32 122.6 6.2 19.8 4.3
122.8 6.3 19.5 4.4
321.5 494.8 0.32 124.4 6.4 19.4 4.5
671.6 1009.6 0.27 76.8 3.7 20.8 2.6
722.7 1086.5 0.36 75.5 3.8 19.9 2.7
Ultimate Tensile Strength (kPa) Estimated True UTS (kPa) Failure Strain Wet Weight (mg) Dry Weight (mg) Wet Weight / Dry Weight Total Protein (mg)
168.5 201.9 0.13 23.8 1.45 16.4 1.08
133.2 177.1 0.21 45.2 2.25 20.1 1.58
223.2 288.0 0.18 24.1 1.85 13.0 1.25
314.5 484.1 0.33 123.0 6.30 19.5 4.40
697.1 1048.0 0.31 76.2 3.75 20.3 2.65
43.1 51.6 0.02 0.6 0.06 0.6 0.03
10.6 14.2 0.03 0.8 0.06 0.4 0.04
9.0 11.6 0.03 0.3 0.06 0.5 0.06
7.2 11.1 0.03 0.9 0.08 0.2 0.08
36.1 54.3 0.06 0.9 0.07 0.6 0.07
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Total Collagen (mg) Total 4-Hydroxyproline (mg) % Collagen Collagen Density (mg/cm3) UTS / Collagen Density (kPa/mg/cm3) Insoluble Collagen Fraction (mg)
0.83 0.088 68.8 14.0 0.018
0.87 0.090 67.2 16.1 13.2 0.021
0.88 0.091 67.4 14.9 15.4 0.019
0.84 0.087 69.6 15.4 14.8 0.021
1.01 0.108 91.8 27.9 4.5 0.016
0.98 0.104 92.9 26.9 7.7 0.016
1.00 0.106 90.5 24.4 8.3 0.014
0.97 0.108 91.9 26.7 5.2 0.014
0.48 0.054 31.1 5.0 23.4 0.007
0.52 0.057 32.5 5.3 26.9 0.007
0.49 0.054 31.6 4.9 28.6 0.006
0.54 0.059 33.7 5.5 24.4 0.006
1.38 0.143 31.4 7.6 40.3 0.180
1.37 0.145 31.8 7.7 40.7 0.166
1.39 0.144 31.6 7.9 0.177
1.46 0.150 32.4 8.1 39.8 0.193
1.73 0.183 66.6 17.4 38.6 0.223
1.82 0.188 67.4 17.5 41.3 0.242
Total Collagen (mg) Total 4-Hydroxyproline (mg) % Collagen Collagen Density (mg/cm3) UTS / Collagen Density (kPa/mg/cm3) Insoluble Collagen Fraction (mg)
0.99 0.107 91.8 26.5 6.4 0.015
0.51 0.056 32.2 5.2 25.9 0.007
0.85 0.089 68.2 15.1 14.5 0.020
1.40 0.146 31.8 7.8 40.3 0.179
1.78 0.186 67.0 17.4 40.0 0.233
0.02 0.002 1.0 1.5 1.9 0.001
0.03 0.002 1.2 0.2 2.4 0.001
0.03 0.002 1.1 0.9 1.1 0.002
0.04 0.003 0.5 0.2 0.4 0.011
0.06 0.004 0.6 0.1 1.9 0.013
…………………………………………………………………………………………………………… 
Insoluble Collagen Fraction (%) Total Proteoglycans and Glycosaminoglycans (µg) % Proteoglycans and Glycosaminoglycans Cell Number (Million)
2.2 31.5 2.6 2.7
2.4 30.8 2.4 2.8
2.2 31.1 2.4 2.6
2.5 31.9 2.7 2.9
1.6 38.3 3.5 2.8
1.6 38.0 3.6 2.9
1.4 38.0 3.5 2.7
1.5 39.4 3.8 2.8
1.5 44.7 2.9 3.9
1.3 46.5 2.9 4.0
1.2 44.5 2.9 4.1
1.1 45.7 2.8 3.8
13.0 65.1 1.5 6.1
12.2 63.9 1.5 6.2
12.7 64.3 1.5 6.0
13.2 63.8 1.4 6.1
12.9 38.6 1.5 3.6
13.3 38.1 1.4 3.5
Insoluble Collagen Fraction (%) Total Proteoglycans and Glycosaminoglycans (µg) % Proteoglycans and Glycosaminoglycans Cell Number (Million)
1.5 38.4 3.6 2.8
1.3 45.4 2.9 4.0
2.3 31.3 2.5 2.8
12.8 64.3 1.5 6.1
13.1 38.4 1.4 3.6
0.1 0.7 0.1 0.1
0.2 0.9 0.0 0.1
0.2 0.5 0.2 0.1
0.5 0.6 0.0 0.1
0.3 0.4 0.1 0.1
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Appendix 5: One-Way Anova and Tukey HSD Post Hoc 
Statistical Analysis of Parameters between all Groups 
  
 
OneWay ANOVA 
   
Sum of 
Squares df Mean Square F Sig. 
Thickness Between Groups .231 4 .058 1879.809 .000
 Within Groups .000 13 .000   
 Total .232 17     
Total Protein Between Groups 29.838 4 7.459 2154.951 .000
 Within Groups .045 13 .003   
 Total 29.883 17     
Cell Number Between Groups 29.718 4 7.429 666.088 .000
 Within Groups .145 13 .011   
 Total 29.863 17     
Tension Between Groups 46558.721 4 11639.680 921.794 .000
 Within Groups 138.899 11 12.627   
 Total 46697.620 15     
UTS Between Groups 492785.018 4 123196.254 181.257 .000
 Within Groups 7476.440 11 679.676   
 Total 500261.458 15     
Failure Strain Between Groups .098 4 .024 23.008 .000
 Within Groups .012 11 .001   
 Total .109 15     
Total Collagen Between Groups 2.879 4 .720 667.044 .000
 Within Groups .014 13 .001   
 Total 2.893 17     
Percent Collagen Between Groups 10535.886 4 2633.972 2919.150 .000
 Within Groups 11.730 13 .902   
 Total 10547.616 17     
Non-Acid and Pepsin 
Extractable Fraction 
Between Groups 502.709 4 125.677 2163.981 .000
 Within Groups .755 13 .058   
 Total 503.464 17     
Total Proteoglycans and 
Glycosaminoglycans 
Between Groups 2482.114 4 620.528 1396.256 .000
 Within Groups 5.777 13 .444   
 Total 2487.891 17     
Percent Proteoglycans 
and Glycosaminoglycans 
Between Groups 11.810 4 2.953 260.226 .000
 Within Groups .148 13 .011   
 Total 11.958 17     
UTS per Collagen 
Density 
Between Groups 2816.691 4 704.173 229.485 .000
 Within Groups 33.753 11 3.068   
 Total 2850.444 15     
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Tukey HSD Post Hoc 
(* The mean difference is significant at the .05 level.) 
Dependent Variable 
(I) 
SampleType 
(J) 
SampleType 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence 
Interval 
      
Lower 
Bound 
Upper 
Bound 
Thickness CDM Collagen Gel .04250(*) .00392 .000 .0301 .0549 
  Fibrin Gel -.09250(*) .00392 .000 -.1049 -.0801 
  *CDM -.27000(*) .00392 .000 -.2824 -.2576 
  **CDM -.10000(*) .00480 .000 -.1151 -.0849 
 Collagen Gel CDM -.04250(*) .00392 .000 -.0549 -.0301 
  Fibrin Gel -.13500(*) .00392 .000 -.1474 -.1226 
  *CDM -.31250(*) .00392 .000 -.3249 -.3001 
  **CDM -.14250(*) .00480 .000 -.1576 -.1274 
 Fibrin Gel CDM .09250(*) .00392 .000 .0801 .1049 
  Collagen Gel .13500(*) .00392 .000 .1226 .1474 
  *CDM -.17750(*) .00392 .000 -.1899 -.1651 
  **CDM -.00750 .00480 .545 -.0226 .0076 
 *CDM CDM .27000(*) .00392 .000 .2576 .2824 
  Collagen Gel .31250(*) .00392 .000 .3001 .3249 
  Fibrin Gel .17750(*) .00392 .000 .1651 .1899 
  **CDM .17000(*) .00480 .000 .1549 .1851 
 **CDM CDM .10000(*) .00480 .000 .0849 .1151 
  Collagen Gel .14250(*) .00480 .000 .1274 .1576 
  Fibrin Gel .00750 .00480 .545 -.0076 .0226 
  *CDM -.17000(*) .00480 .000 -.1851 -.1549 
Total Protein CDM Collagen Gel .15000(*) .04160 .022 .0190 .2810 
  Fibrin Gel -.30000(*) .04160 .000 -.4310 -.1690 
  *CDM -3.15000(*) .04160 .000 -3.2810 -3.0190 
  **CDM -1.40000(*) .05095 .000 -1.5604 -1.2396 
 Collagen Gel CDM -.15000(*) .04160 .022 -.2810 -.0190 
  Fibrin Gel -.45000(*) .04160 .000 -.5810 -.3190 
  *CDM -3.30000(*) .04160 .000 -3.4310 -3.1690 
  **CDM -1.55000(*) .05095 .000 -1.7104 -1.3896 
 Fibrin Gel CDM .30000(*) .04160 .000 .1690 .4310 
  Collagen Gel .45000(*) .04160 .000 .3190 .5810 
  *CDM -2.85000(*) .04160 .000 -2.9810 -2.7190 
  **CDM -1.10000(*) .05095 .000 -1.2604 -.9396 
 *CDM CDM 3.15000(*) .04160 .000 3.0190 3.2810 
  Collagen Gel 3.30000(*) .04160 .000 3.1690 3.4310 
  Fibrin Gel 2.85000(*) .04160 .000 2.7190 2.9810 
  **CDM 1.75000(*) .05095 .000 1.5896 1.9104 
 **CDM CDM 1.40000(*) .05095 .000 1.2396 1.5604 
  Collagen Gel 1.55000(*) .05095 .000 1.3896 1.7104 
  Fibrin Gel 1.10000(*) .05095 .000 .9396 1.2604 
  *CDM -1.75000(*) .05095 .000 -1.9104 -1.5896 
Cell Number CDM Collagen Gel -.05000 .07468 .960 -.2851 .1851 
  Fibrin Gel -1.20000(*) .07468 .000 -1.4351 -.9649 
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  *CDM -3.35000(*) .07468 .000 -3.5851 -3.1149 
  **CDM -.80000(*) .09146 .000 -1.0880 -.5120 
 Collagen Gel CDM .05000 .07468 .960 -.1851 .2851 
  Fibrin Gel -1.15000(*) .07468 .000 -1.3851 -.9149 
  *CDM -3.30000(*) .07468 .000 -3.5351 -3.0649 
  **CDM -.75000(*) .09146 .000 -1.0380 -.4620 
 Fibrin Gel CDM 1.20000(*) .07468 .000 .9649 1.4351 
  Collagen Gel 1.15000(*) .07468 .000 .9149 1.3851 
  *CDM -2.15000(*) .07468 .000 -2.3851 -1.9149 
  **CDM .40000(*) .09146 .006 .1120 .6880 
 *CDM CDM 3.35000(*) .07468 .000 3.1149 3.5851 
  Collagen Gel 3.30000(*) .07468 .000 3.0649 3.5351 
  Fibrin Gel 2.15000(*) .07468 .000 1.9149 2.3851 
  **CDM 2.55000(*) .09146 .000 2.2620 2.8380 
 **CDM CDM .80000(*) .09146 .000 .5120 1.0880 
  Collagen Gel .75000(*) .09146 .000 .4620 1.0380 
  Fibrin Gel -.40000(*) .09146 .006 -.6880 -.1120 
  *CDM -2.55000(*) .09146 .000 -2.8380 -2.2620 
Tension CDM Collagen Gel 14.00000(*) 2.71401 .002 5.2228 22.7772 
  Fibrin Gel -1.07500 2.71401 .994 -9.8522 7.7022 
  *CDM -96.33333(*) 2.90140 .000 -105.7165 -86.9501 
  **CDM -128.95000(*) 3.24387 .000 -139.4407 -118.4593 
 Collagen Gel CDM -14.00000(*) 2.71401 .002 -22.7772 -5.2228 
  Fibrin Gel -15.07500(*) 2.51269 .001 -23.2011 -6.9489 
  *CDM -110.33333(*) 2.71401 .000 -119.1105 -101.5562 
  **CDM -142.95000(*) 3.07740 .000 -152.9024 -132.9976 
 Fibrin Gel CDM 1.07500 2.71401 .994 -7.7022 9.8522 
  Collagen Gel 15.07500(*) 2.51269 .001 6.9489 23.2011 
  *CDM -95.25833(*) 2.71401 .000 -104.0355 -86.4812 
  **CDM -127.87500(*) 3.07740 .000 -137.8274 -117.9226 
 *CDM CDM 96.33333(*) 2.90140 .000 86.9501 105.7165 
  Collagen Gel 110.33333(*) 2.71401 .000 101.5562 119.1105 
  Fibrin Gel 95.25833(*) 2.71401 .000 86.4812 104.0355 
  **CDM -32.61667(*) 3.24387 .000 -43.1074 -22.1259 
 **CDM CDM 128.95000(*) 3.24387 .000 118.4593 139.4407 
  Collagen Gel 142.95000(*) 3.07740 .000 132.9976 152.9024 
  Fibrin Gel 127.87500(*) 3.07740 .000 117.9226 137.8274 
  *CDM 32.61667(*) 3.24387 .000 22.1259 43.1074 
UTS CDM Collagen Gel 54.72500 19.91175 .109 -9.6700 119.1200 
  Fibrin Gel 89.97500(*) 19.91175 .006 25.5800 154.3700 
  *CDM -91.30000(*) 21.28656 .009 -160.1412 -22.4588 
  **CDM -473.95000(*) 23.79910 .000 -550.9168 -396.9832 
 Collagen Gel CDM -54.72500 19.91175 .109 -119.1200 9.6700 
  Fibrin Gel 35.25000 18.43470 .366 -24.3682 94.8682 
  *CDM -146.02500(*) 19.91175 .000 -210.4200 -81.6300 
  **CDM -528.67500(*) 22.57780 .000 -601.6921 -455.6579 
 Fibrin Gel CDM -89.97500(*) 19.91175 .006 -154.3700 -25.5800 
  Collagen Gel -35.25000 18.43470 .366 -94.8682 24.3682 
  *CDM -181.27500(*) 19.91175 .000 -245.6700 -116.8800 
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  **CDM -563.92500(*) 22.57780 .000 -636.9421 -490.9079 
 *CDM CDM 91.30000(*) 21.28656 .009 22.4588 160.1412 
  Collagen Gel 146.02500(*) 19.91175 .000 81.6300 210.4200 
  Fibrin Gel 181.27500(*) 19.91175 .000 116.8800 245.6700 
  **CDM -382.65000(*) 23.79910 .000 -459.6168 -305.6832 
 **CDM CDM 473.95000(*) 23.79910 .000 396.9832 550.9168 
  Collagen Gel 528.67500(*) 22.57780 .000 455.6579 601.6921 
  Fibrin Gel 563.92500(*) 22.57780 .000 490.9079 636.9421 
  *CDM 382.65000(*) 23.79910 .000 305.6832 459.6168 
Failure Strain CDM Collagen Gel .04667 .02486 .382 -.0337 .1271 
  Fibrin Gel -.03083 .02486 .730 -.1112 .0496 
  *CDM -.16000(*) .02658 .001 -.2460 -.0740 
  **CDM -.13833(*) .02972 .005 -.2344 -.0422 
 Collagen Gel CDM -.04667 .02486 .382 -.1271 .0337 
  Fibrin Gel -.07750(*) .02302 .040 -.1519 -.0031 
  *CDM -.20667(*) .02486 .000 -.2871 -.1263 
  **CDM -.18500(*) .02819 .000 -.2762 -.0938 
 Fibrin Gel CDM .03083 .02486 .730 -.0496 .1112 
  Collagen Gel .07750(*) .02302 .040 .0031 .1519 
  *CDM -.12917(*) .02486 .002 -.2096 -.0488 
  **CDM -.10750(*) .02819 .019 -.1987 -.0163 
 *CDM CDM .16000(*) .02658 .001 .0740 .2460 
  Collagen Gel .20667(*) .02486 .000 .1263 .2871 
  Fibrin Gel .12917(*) .02486 .002 .0488 .2096 
  **CDM .02167 .02972 .945 -.0744 .1178 
 **CDM CDM .13833(*) .02972 .005 .0422 .2344 
  Collagen Gel .18500(*) .02819 .000 .0938 .2762 
  Fibrin Gel .10750(*) .02819 .019 .0163 .1987 
  *CDM -.02167 .02972 .945 -.1178 .0744 
Total Collagen CDM Collagen Gel -.13500(*) .02323 .000 -.2081 -.0619 
  Fibrin Gel .34750(*) .02323 .000 .2744 .4206 
  *CDM -.54500(*) .02323 .000 -.6181 -.4719 
  **CDM -.92000(*) .02845 .000 -1.0096 -.8304 
 Collagen Gel CDM .13500(*) .02323 .000 .0619 .2081 
  Fibrin Gel .48250(*) .02323 .000 .4094 .5556 
  *CDM -.41000(*) .02323 .000 -.4831 -.3369 
  **CDM -.78500(*) .02845 .000 -.8746 -.6954 
 Fibrin Gel CDM -.34750(*) .02323 .000 -.4206 -.2744 
  Collagen Gel -.48250(*) .02323 .000 -.5556 -.4094 
  *CDM -.89250(*) .02323 .000 -.9656 -.8194 
  **CDM -1.26750(*) .02845 .000 -1.3571 -1.1779 
 *CDM CDM .54500(*) .02323 .000 .4719 .6181 
  Collagen Gel .41000(*) .02323 .000 .3369 .4831 
  Fibrin Gel .89250(*) .02323 .000 .8194 .9656 
  **CDM -.37500(*) .02845 .000 -.4646 -.2854 
 **CDM CDM .92000(*) .02845 .000 .8304 1.0096 
  Collagen Gel .78500(*) .02845 .000 .6954 .8746 
  Fibrin Gel 1.26750(*) .02845 .000 1.1779 1.3571 
  *CDM .37500(*) .02845 .000 .2854 .4646 
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Percent Collagen CDM Collagen Gel -23.52500(*) .67168 .000 -25.6399 -21.4101 
  Fibrin Gel 36.02500(*) .67168 .000 33.9101 38.1399 
  *CDM 36.45000(*) .67168 .000 34.3351 38.5649 
  **CDM 1.30000 .82264 .534 -1.2902 3.8902 
 Collagen Gel CDM 23.52500(*) .67168 .000 21.4101 25.6399 
  Fibrin Gel 59.55000(*) .67168 .000 57.4351 61.6649 
  *CDM 59.97500(*) .67168 .000 57.8601 62.0899 
  **CDM 24.82500(*) .82264 .000 22.2348 27.4152 
 Fibrin Gel CDM -36.02500(*) .67168 .000 -38.1399 -33.9101 
  Collagen Gel -59.55000(*) .67168 .000 -61.6649 -57.4351 
  *CDM .42500 .67168 .967 -1.6899 2.5399 
  **CDM -34.72500(*) .82264 .000 -37.3152 -32.1348 
 *CDM CDM -36.45000(*) .67168 .000 -38.5649 -34.3351 
  Collagen Gel -59.97500(*) .67168 .000 -62.0899 -57.8601 
  Fibrin Gel -.42500 .67168 .967 -2.5399 1.6899 
  **CDM -35.15000(*) .82264 .000 -37.7402 -32.5598 
 **CDM CDM -1.30000 .82264 .534 -3.8902 1.2902 
  Collagen Gel -24.82500(*) .82264 .000 -27.4152 -22.2348 
  Fibrin Gel 34.72500(*) .82264 .000 32.1348 37.3152 
  *CDM 35.15000(*) .82264 .000 32.5598 37.7402 
Non-Acid and Pepsin 
Extractable Fraction 
CDM Collagen Gel .80000(*) .17041 .003 .2634 1.3366 
  Fibrin Gel 1.02500(*) .17041 .000 .4884 1.5616 
  *CDM -10.47500(*) .17041 .000 -11.0116 -9.9384 
  **CDM -10.77500(*) .20870 .000 -11.4321 -10.1179 
 Collagen Gel CDM -.80000(*) .17041 .003 -1.3366 -.2634 
  Fibrin Gel .22500 .17041 .684 -.3116 .7616 
  *CDM -11.27500(*) .17041 .000 -11.8116 -10.7384 
  **CDM -11.57500(*) .20870 .000 -12.2321 -10.9179 
 Fibrin Gel CDM -1.02500(*) .17041 .000 -1.5616 -.4884 
  Collagen Gel -.22500 .17041 .684 -.7616 .3116 
  *CDM -11.50000(*) .17041 .000 -12.0366 -10.9634 
  **CDM -11.80000(*) .20870 .000 -12.4571 -11.1429 
 *CDM CDM 10.47500(*) .17041 .000 9.9384 11.0116 
  Collagen Gel 11.27500(*) .17041 .000 10.7384 11.8116 
  Fibrin Gel 11.50000(*) .17041 .000 10.9634 12.0366 
  **CDM -.30000 .20870 .616 -.9571 .3571 
 **CDM CDM 10.77500(*) .20870 .000 10.1179 11.4321 
  Collagen Gel 11.57500(*) .20870 .000 10.9179 12.2321 
  Fibrin Gel 11.80000(*) .20870 .000 11.1429 12.4571 
  *CDM .30000 .20870 .616 -.3571 .9571 
Total Proteoglycans and 
Glycosaminoglycans 
CDM Collagen Gel -7.10000(*) .47139 .000 -8.5843 -5.6157 
  Fibrin Gel -14.02500(*) .47139 .000 -15.5093 -12.5407 
  *CDM -32.95000(*) .47139 .000 -34.4343 -31.4657 
  **CDM -7.02500(*) .57734 .000 -8.8428 -5.2072 
 Collagen Gel CDM 7.10000(*) .47139 .000 5.6157 8.5843 
  Fibrin Gel -6.92500(*) .47139 .000 -8.4093 -5.4407 
  *CDM -25.85000(*) .47139 .000 -27.3343 -24.3657 
  **CDM .07500 .57734 1.000 -1.7428 1.8928 
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 Fibrin Gel CDM 14.02500(*) .47139 .000 12.5407 15.5093 
  Collagen Gel 6.92500(*) .47139 .000 5.4407 8.4093 
  *CDM -18.92500(*) .47139 .000 -20.4093 -17.4407 
  **CDM 7.00000(*) .57734 .000 5.1822 8.8178 
 *CDM CDM 32.95000(*) .47139 .000 31.4657 34.4343 
  Collagen Gel 25.85000(*) .47139 .000 24.3657 27.3343 
  Fibrin Gel 18.92500(*) .47139 .000 17.4407 20.4093 
  **CDM 25.92500(*) .57734 .000 24.1072 27.7428 
 **CDM CDM 7.02500(*) .57734 .000 5.2072 8.8428 
  Collagen Gel -.07500 .57734 1.000 -1.8928 1.7428 
  Fibrin Gel -7.00000(*) .57734 .000 -8.8178 -5.1822 
  *CDM -25.92500(*) .57734 .000 -27.7428 -24.1072 
Percent Proteoglycans 
and Glycosaminoglycans 
CDM Collagen Gel -1.07500(*) .07532 .000 -1.3122 -.8378 
  Fibrin Gel -.35000(*) .07532 .003 -.5872 -.1128 
  *CDM 1.05000(*) .07532 .000 .8128 1.2872 
  **CDM 1.07500(*) .09225 .000 .7845 1.3655 
 Collagen Gel CDM 1.07500(*) .07532 .000 .8378 1.3122 
  Fibrin Gel .72500(*) .07532 .000 .4878 .9622 
  *CDM 2.12500(*) .07532 .000 1.8878 2.3622 
  **CDM 2.15000(*) .09225 .000 1.8595 2.4405 
 Fibrin Gel CDM .35000(*) .07532 .003 .1128 .5872 
  Collagen Gel -.72500(*) .07532 .000 -.9622 -.4878 
  *CDM 1.40000(*) .07532 .000 1.1628 1.6372 
  **CDM 1.42500(*) .09225 .000 1.1345 1.7155 
 *CDM CDM -1.05000(*) .07532 .000 -1.2872 -.8128 
  Collagen Gel -2.12500(*) .07532 .000 -2.3622 -1.8878 
  Fibrin Gel -1.40000(*) .07532 .000 -1.6372 -1.1628 
  **CDM .02500 .09225 .999 -.2655 .3155 
 **CDM CDM -1.07500(*) .09225 .000 -1.3655 -.7845 
  Collagen Gel -2.15000(*) .09225 .000 -2.4405 -1.8595 
  Fibrin Gel -1.42500(*) .09225 .000 -1.7155 -1.1345 
  *CDM -.02500 .09225 .999 -.3155 .2655 
UTS per Collagen 
Density 
CDM Collagen Gel 8.04167(*) 1.33789 .001 3.7149 12.3684 
  Fibrin Gel -11.35833(*) 1.33789 .000 -15.6851 -7.0316 
  *CDM -25.80000(*) 1.43026 .000 -30.4255 -21.1745 
  **CDM -25.48333(*) 1.59908 .000 -30.6548 -20.3119 
 Collagen Gel CDM -8.04167(*) 1.33789 .001 -12.3684 -3.7149 
  Fibrin Gel -19.40000(*) 1.23865 .000 -23.4058 -15.3942 
  *CDM -33.84167(*) 1.33789 .000 -38.1684 -29.5149 
  **CDM -33.52500(*) 1.51702 .000 -38.4311 -28.6189 
 Fibrin Gel CDM 11.35833(*) 1.33789 .000 7.0316 15.6851 
  Collagen Gel 19.40000(*) 1.23865 .000 15.3942 23.4058 
  *CDM -14.44167(*) 1.33789 .000 -18.7684 -10.1149 
  **CDM -14.12500(*) 1.51702 .000 -19.0311 -9.2189 
 *CDM CDM 25.80000(*) 1.43026 .000 21.1745 30.4255 
  Collagen Gel 33.84167(*) 1.33789 .000 29.5149 38.1684 
  Fibrin Gel 14.44167(*) 1.33789 .000 10.1149 18.7684 
  **CDM .31667 1.59908 1.000 -4.8548 5.4881 
Jan-Eric W. Ahlfors 
  95
 **CDM CDM 25.48333(*) 1.59908 .000 20.3119 30.6548 
  Collagen Gel 33.52500(*) 1.51702 .000 28.6189 38.4311 
  Fibrin Gel 14.12500(*) 1.51702 .000 9.2189 19.0311 
  *CDM -.31667 1.59908 1.000 -5.4881 4.8548 
*  The mean difference is significant at the .05 level. 
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Appendix 6: Arrangement of Collagen in Cell-Derived Matrices 
 
 
The collagen in the cell-derived matrices organized into several layers of 
alternating alignment where fibers were parallel to each other within layers, but at right 
angles to adjacent fibers in layers. 
 
 
 
 
